165800-06-6 | Zoledronic acid hydrate

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
50mg	98%	in stock	$8.00	$6.00
1g	98%	in stock	$32.00	$22.00
5g	98%	in stock	$79.00	$55.00
10g	98%	in stock	$155.00	$108.00
25g	98%	in stock	$325.00	$228.00
100g	98%	in stock	$1,024.00	$717.00

Description

• Catalog Number: AA88411
• Chemical Name: Zoledronic acid hydrate
• CAS Number: 165800-06-6
• Molecular Formula: C5H12N2O8P2
• Molecular Weight: 290.1049
• MDL Number: MFCD18426508
• SMILES: OP(=O)(C(P(=O)(O)O)(Cn1cncc1)O)O.O

Computed Properties

• Complexity: 327
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 17
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 6
• Rotatable Bond Count: 4

Literature

• Interleukin-19 as a translational indicator of renal injury.

  Archives of toxicology 20150101

• Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.

  Biochimica et biophysica acta 20121201

• Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20121101

• Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.

  The Journal of steroid biochemistry and molecular biology 20121101

• The effect of systemically administrated zoledronic acid on the osseointegration of dental implants.

  Oral diseases 20121101

• The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20121101

• Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

  European journal of cancer (Oxford, England : 1990) 20121101

• (89)Sr imaging with bremsstrahlung in patients with metastatic breast cancer.

  Clinical nuclear medicine 20121101

• Radiographic evaluation of maxillofacial region in oncology patients treated with bisphosphonates.

  Oral surgery, oral medicine, oral pathology and oral radiology 20121101

• Fracture risk and zoledronic acid therapy in men with osteoporosis.

  The New England journal of medicine 20121101

• Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.

  Blood 20121018

• [Should we treat thalassemia-induced osteoporosis: two case reports].

  Praxis 20121003

• Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw.

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20121001

• Antiresorptive therapies in oncology and their effects on cancer progression.

  Cancer treatment reviews 20121001

• Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20121001

• Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20121001

• Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes.

  Bone 20121001

• Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.

  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 20121001

• Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20121001

• Acute anterior uveitis following zoledronic acid infusion for osteoporosis.

  Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 20121001

• Persistence with intravenous zoledronate in elderly patients with osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120901

• Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

  Cancer immunology, immunotherapy : CII 20120901

• Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.

  Journal of cellular and molecular medicine 20120901

• Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120901

• Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro.

  Prostate cancer and prostatic diseases 20120901

• Tooth extraction in patients on zoledronic acid therapy.

  Oral oncology 20120901

• Renal complications from bisphosphonate treatment.

  Current opinion in supportive and palliative care 20120901

• Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.

  Molecular pharmacology 20120901

• Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.

  Current opinion in supportive and palliative care 20120901

• Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis.

  Asian Pacific journal of tropical medicine 20120901

• Preventing bone complications in prostate cancer.

  Current opinion in supportive and palliative care 20120901

• Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120901

• [Therapeutic effect of zoledronic acid on primary osteoporosis in elderly patients].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20120901

• Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.

  Anticancer research 20120901

• Denosumab and bone metastases. No better than a bisphosphonate.

  Prescrire international 20120901

• Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.

  International journal of cancer 20120815

• Zoledronic acid, an aminobisphosphonate, prolongs survival of skin allografts.

  Clinical and investigative medicine. Medecine clinique et experimentale 20120804

• Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.

  Investigational new drugs 20120801

• New treatment options for patients with metastatic castration-resistant prostate cancer.

  Cancer treatment reviews 20120801

• Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.

  Cancer treatment reviews 20120801

• Low concentration amino-bisphosphonates stimulate human keratinocyte proliferation and in vitro wound healing.

  International wound journal 20120801

• Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120801

• Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial.

  Annals of the rheumatic diseases 20120801

• Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120801

• Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120801

• Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.

  Expert review of pharmacoeconomics & outcomes research 20120801

• A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.

  American journal of clinical oncology 20120801

• Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120801

• Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.

  Clinical breast cancer 20120801

• Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.

  The Journal of clinical endocrinology and metabolism 20120801

• Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120801

• [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].

  Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20120801

• [Management of bone metastasis originating from lung cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120801

• Effect and mechanism of zoledronate on prevention of collapse in osteonecrosis of the femoral head.

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20120801

• Effects of bone-targeted agents on cancer progression and mortality.

  Journal of the National Cancer Institute 20120718

• Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.

  Journal of cellular and molecular medicine 20120701

• Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120701

• Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes.

  Archives of oral biology 20120701

• Complete remission and long-term survival in a child with relapsed medulloblastoma with extensive osteosclerotic bony metastasis with a novel metronomic chemobiological approach.

  Journal of pediatric hematology/oncology 20120701

• Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.

  Arthritis care & research 20120701

• Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120701

• Zoledronic acid improves bone mineral density in pediatric spinal cord injury.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120701

• Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.

  Current medical research and opinion 20120701

• Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20120701

• Efficacy of zoledronic acid in treatment of teoarthritis is dependent on the disease progression stage in rat medial meniscal tear model.

  Acta pharmacologica Sinica 20120701

• What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120701

• [A survey of the dosage of zoledronic acid and investigation of the relationship between renal function and adverse events].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120701

• [Zoledronic acid incorporated in chitosan/calcium phosphate ceramic: characterization and in vitro response of osteoblast cells].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20120701

• Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.

  British journal of cancer 20120626

• Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

  Blood 20120607

• Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells.

  Medical oncology (Northwood, London, England) 20120601

• Small cell carcinoma of the urinary bladder with hypercalcemia.

  Medical oncology (Northwood, London, England) 20120601

• Suppurative arthritis of the temporomandibular joint associated with bisphosphonate: a case report.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120601

• New role for an established drug? Bisphosphonates as potential anticancer agents.

  Prostate cancer and prostatic diseases 20120601

• Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.

  Breast cancer research and treatment 20120601

• Lip ulceration associated with intravenous administration of zoledronic acid: report of a case.

  Head and neck pathology 20120601

• Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.

  Breast cancer research and treatment 20120601

• Calcium phosphate cement delivering zoledronate decreases bone turnover rate and restores bone architecture in ovariectomized rats.

  Biomedical materials (Bristol, England) 20120601

• Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.

  The Journal of clinical endocrinology and metabolism 20120601

• Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.

  Bone 20120601

• Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.

  Clinical therapeutics 20120601

• Use of zoledronate for treatment of a bone fragility disorder in horses.

  Journal of the American Veterinary Medical Association 20120601

• Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw.

  Australian dental journal 20120601

• Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.

  The Canadian journal of urology 20120601

• Re: Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.

  The Canadian journal of urology 20120601

• [The importance of bone management for cancer bone disease--positioning of zoledronic acid for multiple myeloma, genitor-urinary cancers (renal cancer and prostate cancer), lung cancer and breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120601

• [Bisphosphonate related osteonecrosis of the jaws: a case report and review of the literature].

  Shanghai kou qiang yi xue = Shanghai journal of stomatology 20120601

• Bisphosphonates in multiple myeloma: a network meta-analysis.

  The Cochrane database of systematic reviews 20120516

• Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120501

• Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20120501

• Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.

  Oncology reports 20120501

• 'Atypical femoral fractures' during bisphosphonate exposure in adult hypophosphatasia.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120501

• Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.

  Bone 20120501

• Development of superior bone scintigraphic agent from a series of (99m)Tc-labeled zoledronic acid derivatives.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20120501

• Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.

  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20120501

• Cellular interactions of synovial fluid γδ T cells in juvenile idiopathic arthritis.

  Journal of immunology (Baltimore, Md. : 1950) 20120501

• Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.

  American journal of hematology 20120501

• Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120501

• Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.

  PharmacoEconomics 20120501

• Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.

  The oncologist 20120501

• Orthodontic tooth movement and root resorption in ovariectomized rats treated by systemic administration of zoledronic acid.

  American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 20120501

• [Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon human nasopharyngeal carcinoma cell line HNE1].

  Zhonghua yi xue za zhi 20120424

• Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.

  Cancer 20120415

• Pathophysiology and new strategies for the treatment of Legg-Calvé-Perthes disease.

  The Journal of bone and joint surgery. American volume 20120404

• An extensive hemimelic polyostotic fibrous dysplasia: a case report.

  Rheumatology international 20120401

• Effects of zoledronic acid on sutural bone formation: a computed tomography study.

  European journal of orthodontics 20120401

• Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?

  World journal of urology 20120401

• Awareness and education of patients receiving bisphosphonates.

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20120401

• The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120401

• Possible zoledronic acid-induced dermatomyositis.

  Clinical and experimental dermatology 20120401

• Lessons learned from an osteoporosis clinical trial in frail long-term care residents.

  Clinical trials (London, England) 20120401

• Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma.

  Clinical lymphoma, myeloma & leukemia 20120401

• The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery.

  Acta neurochirurgica 20120401

• Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.

  Calcified tissue international 20120401

• Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1.

  Journal of immunology (Baltimore, Md. : 1950) 20120401

• Bisphosphonate-associated orbital inflammation--a case report and review.

  Orbit (Amsterdam, Netherlands) 20120401

• Efficacy of vinorelbine and zoledronate combination therapy against postoperative recurrence of lung cancer.

  Gan to kagaku ryoho. Cancer & chemotherapy 20120401

• Myeloma: diagnosis complications and supportive care.

  Hematology (Amsterdam, Netherlands) 20120401

• Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.

  Hospital practice (1995) 20120401

• Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.

  Journal of controlled release : official journal of the Controlled Release Society 20120328

• Regression of giant cell tumor of the cervical spine with bisphosphonate as single therapy.

  Spine 20120315

• Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity.

  Proceedings of the National Academy of Sciences of the United States of America 20120313

• Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers.

  Chemical communications (Cambridge, England) 20120311

• Paget's disease of bone: analysis of 134 cases from an island in Southern Brazil: another cluster of Paget's disease of bone in South America.

  Rheumatology international 20120301

• Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120301

• Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.

  Cancer immunology, immunotherapy : CII 20120301

• Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120301

• Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.

  Cancer 20120301

• Data from extension trials: denosumab and zoledronic acid.

  Current osteoporosis reports 20120301

• Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20120301

• [Renal insufficiency and breast cancer].

  Bulletin du cancer 20120301

• Femoral stress fractures associated with long-term bisphosphonate treatment.

  Clinical orthopaedics and related research 20120301

• Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells.

  Bone 20120301

• Denosumab for the management of bone disease in patients with solid tumors.

  Expert review of anticancer therapy 20120301

• Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.

  Bone 20120301

• Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?

  Clinical genitourinary cancer 20120301

• Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.

  Current osteoporosis reports 20120301

• [Combination or sequential treatment using PTH and anti-resorption therapies].

  Clinical calcium 20120301

• Paget disease of bone - an update.

  Australian family physician 20120301

• Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?

  Singapore medical journal 20120301

• Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.

  Clinical oral investigations 20120201

• The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

  Clinical oral investigations 20120201

• Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120201

• Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120201

• Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.

  BJU international 20120201

• Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120201

• Bisphosphonates and breast cancer prevention.

  Anti-cancer agents in medicinal chemistry 20120201

• Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.

  Anti-cancer agents in medicinal chemistry 20120201

• Anticancer activity of bisphosphonates in breast cancer.

  Anti-cancer agents in medicinal chemistry 20120201

• Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?

  Anti-cancer agents in medicinal chemistry 20120201

• Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.

  Clinical breast cancer 20120201

• Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.

  Cytotherapy 20120201

• Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?

  Current oncology reports 20120201

• Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.

  International journal of urology : official journal of the Japanese Urological Association 20120201

• The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.

  Clinical lymphoma, myeloma & leukemia 20120201

• The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120201

• Histopathological features of osteonecrosis of the jaw associated with bisphosphonates.

  Histopathology 20120201

• Bisphosphonate therapy for osteoporosis: the long and short of it.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20120201

• [Multiple myeloma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20120201

• Atypical insufficiency type femoral stress fractures in patient on bisphosphonates.

  Medicine and health, Rhode Island 20120201

• MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis.

  Oncogene 20120126

• Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.

  Blood 20120112

• Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20120101

• Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101

• New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.

  Biotechnology advances 20120101

• Zoledronate and pamidronate depress neutrophil functions and survival in mice.

  British journal of pharmacology 20120101

• Number needed to treat is incorrect without proper time-related considerations.

  Journal of clinical epidemiology 20120101

• Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.

  Anti-cancer drugs 20120101

• Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.

  Oral oncology 20120101

• Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.

  Cancer science 20120101

• The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.

  European journal of haematology 20120101

• Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.

  Clinical transplantation 20120101

• The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells in vitro.

  Biomaterials 20120101

• Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.

  Journal of medical economics 20120101

• Effect of zoledronate acid treatment on osseointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbits.

  Bone 20120101

• Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.

  Bone 20120101

• Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.

  The Journal of clinical endocrinology and metabolism 20120101

• Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid.

  Calcified tissue international 20120101

• The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.

  European journal of cancer (Oxford, England : 1990) 20120101

• Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.

  Endocrinology 20120101

• Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.

  Journal of medical economics 20120101

• Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.

  Journal of medical economics 20120101

• Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20120101

• Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.

  Journal of medical economics 20120101

• Site specific effects of zoledronic acid during tibial and mandibular fracture repair.

  PloS one 20120101

• Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

  Journal of medical economics 20120101

• Effect of local zoledronate on implant osseointegration in a rat model.

  BMC musculoskeletal disorders 20120101

• Platelet-rich plasma improves wound healing in multiple myeloma bisphosphonate-associated osteonecrosis of the jaw patients.

  Journal of biological regulators and homeostatic agents 20120101

• Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates.

  BMJ case reports 20120101

• Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells.

  PloS one 20120101

• Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.

  BMC cancer 20120101

• Treatment of osteonecrosis of the jaw (ONJ) by medical ozone gas insufflation. A case report.

  Tumori 20120101

• Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.

  PloS one 20120101

• Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells.

  PloS one 20120101

• Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.

  Journal of pediatric endocrinology & metabolism : JPEM 20120101

• Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.

  Endokrynologia Polska 20120101

• Management of bone metastases in refractory prostate cancer--role of denosumab.

  Clinical interventions in aging 20120101

• Zoledronate attenuates angiogenic effects of angiotensin II-stimulated endothelial progenitor cells via RhoA and MAPK signaling.

  PloS one 20120101

• Short-term effects of zoledronate on the histomorphology of osteoclast in young albino rats.

  Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft 20111220

• Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.

  The European journal of health economics : HEPAC : health economics in prevention and care 20111201

• Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20111201

• Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111201

• Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.

  Nanomedicine : nanotechnology, biology, and medicine 20111201

• In vivo assessment of local effects after application of bone screws delivering bisphosphonates into a compromised cancellous bone site.

  Clinical biomechanics (Bristol, Avon) 20111201

• Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.

  Breast cancer research and treatment 20111201

• Anti-osteoporotic drug release from ordered mesoporous bioceramics: experiments and modeling.

  AAPS PharmSciTech 20111201

• Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.

  Clinical genitourinary cancer 20111201

• A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20111201

• Zoledronic acid modulates maturation of human monocyte-derived dendritic cells.

  Experimental biology and medicine (Maywood, N.J.) 20111201

• Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.

  Journal of Korean medical science 20111201

• [Factors associated with acute febrile reaction in elderly patients receiving intravenous zoledronic acid for osteoporosis].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20111201

• AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.

  Oncology (Williston Park, N.Y.) 20111115

• Modern management of malignant hypercalcemia.

  The American journal of hospice & palliative care 20111101

• Zoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production.

  Journal of cellular biochemistry 20111101

• Matrix metalloproteinase-9 expression in alveolar extraction sockets of Zoledronic acid-treated rats.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20111101

• Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?

  Lasers in medical science 20111101

• Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.

  Bone 20111101

• A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.

  Journal of lipid research 20111101

• In vitro generation of mature human osteoclasts.

  Calcified tissue international 20111101

• Economic evaluation of clodronate and zoledronate in patients diagnosed with metastatic bone disease from the perspective of public and third party payors in Brazil.

  Clinical therapeutics 20111101

• Antiangiogenic effects of zoledronate on cancer neovasculature.

  Future oncology (London, England) 20111101

• [A very elderly case of advanced gastric cancer with disseminated carcinomatosis of bone marrow and multiple bone metastasis, diagnosed by extremely elevated serum alkaline phosphatase levels, and treated with low-dose S-1 to avoid disseminated intravascular coagulation].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20111101

• Once-yearly zoledronic acid in older men compared with women with recent hip fracture.

  Journal of the American Geriatrics Society 20111101

• The case of the overlooked osteoclasts.

  ONS connect 20111101

• Ask the doctor. I'm looking for information on Prolia and Reclast as alternatives to Boniva.

  Harvard women's health watch 20111101

• Breast-cancer adjuvant therapy with zoledronic acid.

  The New England journal of medicine 20111013

• Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature.

  Seminars in arthritis and rheumatism 20111001

• Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.

  Cancer immunology, immunotherapy : CII 20111001

• Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20111001

• Manipulation of the anabolic and catabolic responses with BMP-2 and zoledronic acid in a rat femoral fracture model.

  Bone 20111001

• Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20111001

• Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma.

  Journal of cancer research and clinical oncology 20111001

• New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.

  Cancer investigation 20111001

• Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

  Journal of managed care pharmacy : JMCP 20111001

• [Inflammation of the jaws during treatment with bisphosphonates].

  Deutsche medizinische Wochenschrift (1946) 20111001

• DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.

  Blood 20110908

• Zoledronate activates NK cells.

  Blood 20110908

• Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.

  British journal of cancer 20110906

• Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.

  American journal of therapeutics 20110901

• Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78.

  International orthopaedics 20110901

• Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110901

• Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110901

• A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: the IVORY trial Methodological considerations.

  Contemporary clinical trials 20110901

• A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110901

• Antitumor effects of bisphosphonates: from the laboratory to the clinic.

  Current opinion in supportive and palliative care 20110901

• Denosumab: benefits of RANK ligand inhibition in cancer patients.

  Current opinion in supportive and palliative care 20110901

• Bisphosphonate-associated osteonecrosis of the jaw: a six-year history of a case.

  The New Zealand dental journal 20110901

• [Inhibitory effects of zoledronic acid on cell proliferation and invasion in human nasopharyngeal carcinoma cell line HNE1].

  Zhonghua yi xue za zhi 20110830

• Further analyses of the Myeloma IX Study.

  Lancet (London, England) 20110827

• Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid.

  The Journal of biological chemistry 20110819

• Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.

  Journal of immunology (Baltimore, Md. : 1950) 20110815

• Dosing of zoledronic acid throughout the treatment continuum in breast cancer.

  Critical reviews in oncology/hematology 20110801

• Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110801

• Association between timing of zoledronic acid infusion and hip fracture healing.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110801

• A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.

  British journal of haematology 20110801

• Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.

  Cancer immunology, immunotherapy : CII 20110801

• Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20110801

• Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20110801

• A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.

  Pediatric blood & cancer 20110801

• A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies.

  Acta orthopaedica 20110801

• Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.

  Clinical lymphoma, myeloma & leukemia 20110801

• Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.

  Clinical breast cancer 20110801

• Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate.

  The Journal of bone and joint surgery. British volume 20110801

• Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

  The Lancet. Oncology 20110801

• Zoledronic acid for all patients with newly diagnosed multiple myeloma?

  The Lancet. Oncology 20110801

• Pharmacist-run zoledronic acid clinic.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110801

• Bone health medications: research questions versus clinical choices.

  Menopause (New York, N.Y.) 20110801

• Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.

  Menopause (New York, N.Y.) 20110801

• Subtrochanteric fracture in a patient receiving zoledronic acid therapy for metastatic breast cancer.

  Nagoya journal of medical science 20110801

• Teriparitide update.

  Rheumatic diseases clinics of North America 20110801

• Determination of zoledronic acid in human urine and blood plasma using liquid chromatography/electrospray mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110715

• Locally administered zoledronic Acid therapy for giant cell tumor of bone.

  Orthopedics 20110707

• Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women.

  Bone 20110701

• Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20110701

• Osteoclast activity modulates B-cell development in the bone marrow.

  Cell research 20110701

• Seizures associated with zoledronic acid for osteoporosis.

  The Journal of clinical endocrinology and metabolism 20110701

• New developments for treatment and prevention of bone metastases.

  Current opinion in oncology 20110701

• Bisphosphonates inhibit expression of p63 by oral keratinocytes.

  Journal of dental research 20110701

• Pharmacokinetic evaluation of zoledronic acid.

  Expert opinion on drug metabolism & toxicology 20110701

• The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.

  Diabetes care 20110701

• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

  The Lancet. Oncology 20110701

• High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.

  Cancer research 20110701

• Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.

  European journal of cancer (Oxford, England : 1990) 20110701

• Rubber dam clamp trauma, root canal therapy, and osteonecrosis of the jaw.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20110701

• Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.

  International journal of hematology 20110701

• Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative.

  Nuclear medicine and biology 20110701

• Effects of bisphosphonates on sutural bone formation and relapse: A histologic and immunohistochemical study.

  American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 20110701

• Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer.

  Immunotherapy 20110701

• Zoledronic acid: multiplicity of use across the cancer continuum.

  Expert review of anticancer therapy 20110701

• [Therapy for malignancies and inflammatory disorders by modulating human dendritic cell functions].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110701

• Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.

  Anticancer research 20110701

• [Effects of local application of zoledronic acid on bone healing of tooth extraction in rats].

  Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology 20110701

• Safety and efficacy of zoledronic acid in multiple myeloma.

  Lancet (London, England) 20110625

• Safety and efficacy of zoledronic acid in multiple myeloma.

  Lancet (London, England) 20110625

• Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110610

• Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.

  Medical oncology (Northwood, London, England) 20110601

• The influence of zoledronic acid and cyclophosphamide on microcirculation regeneration in healing oral mucosal flaps.

  Archives of oral biology 20110601

• Managing bone health with zoledronic acid: a review of randomized clinical study results.

  Climacteric : the journal of the International Menopause Society 20110601

• Rubber dam clamp trauma during endodontic treatment: a risk factor of bisphosphonate-related osteonecrosis of the jaw?

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20110601

• Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.

  International journal of clinical oncology 20110601

• Effects of zoledronic acid on healing of mandibular fractures: an experimental study in rabbits.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20110601

• Preventive protocol for tooth extractions in patients treated with zoledronate: a case series.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20110601

• Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study.

  Annals of the rheumatic diseases 20110601

• Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates.

  Journal of cellular biochemistry 20110601

• Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

  Breast cancer research and treatment 20110601

• Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.

  International journal of oral and maxillofacial surgery 20110601

• Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.

  Bone 20110601

• A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate.

  British journal of haematology 20110601

• Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series.

  International journal of hematology 20110601

• Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.

  Journal of clinical pharmacy and therapeutics 20110601

• Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer.

  Asia-Pacific journal of clinical oncology 20110601

• The effects of zoledronic acid and hyperbaric oxygen on posterior lumbar fusion in a rabbit model.

  The Journal of bone and joint surgery. British volume 20110601

• Atypical fractures of the femur and ulna and complications of fracture healing in a 76-year-old woman with Sjögren's syndrome.

  Journal of musculoskeletal & neuronal interactions 20110601

• Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.

  Clinical breast cancer 20110601

• [A case of recurrent endometrial cancer metastasis successfully treated with zoledronic Acid].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• [A case of prostate cancer with disseminated carcinomatosis of bone marrow which responded to Zoledronic acid].

  Hinyokika kiyo. Acta urologica Japonica 20110601

• Bisphosphonate-associated osteonecrosis of the jaws -- report of three cases in Bulgaria and review of the literature.

  Acta clinica Croatica 20110601

• Prostate cancer: targeted therapy for prostate cancer metastases to bone.

  Nature reviews. Urology 20110517

• Denosumab for bone metastases from breast cancer: a new therapy option?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110510

• The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.

  Journal of bone and mineral metabolism 20110501

• Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts.

  Archives of oral biology 20110501

• Effect of zoledronic acid on bone healing subsequent to mini-implant insertion.

  The Angle orthodontist 20110501

• No effect of rosuvastatin in the zoledronate-induced acute-phase response.

  Calcified tissue international 20110501

• IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.

  Journal of leukocyte biology 20110501

• Clinical risk factors for recurrent fracture after hip fracture: a prospective study.

  Calcified tissue international 20110501

• Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.

  The Journal of pharmacology and experimental therapeutics 20110501

• Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.

  Oral diseases 20110501

• Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110501

• CCN1, a candidate target for zoledronic acid treatment in breast cancer.

  Molecular cancer therapeutics 20110501

• Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110501

• Effect of zoledronic acid on acro-osteolysis and osteoporosis in a patient with Hajdu-Cheney syndrome.

  Yonsei medical journal 20110501

• The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

  The oncologist 20110501

• Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.

  Journal of the American Dental Association (1939) 20110501

• Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110501

• [A successful case treated with S-1 and zoledronic acid for multiple bone metastasis of breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110501

• Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.

  Leukemia research 20110401

• In vivo effects of zoledronic acid on oral mucosal epithelial cells.

  Oral diseases 20110401

• Multicompartment vectors as novel drug delivery systems: selective activation of Tγδ lymphocytes after zoledronic acid delivery.

  Nanomedicine : nanotechnology, biology, and medicine 20110401

• Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid.

  European urology 20110401

• Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS.

  Biochimica et biophysica acta 20110401

• Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.

  Oncology reports 20110401

• Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases.

  European journal of cancer (Oxford, England : 1990) 20110401

• The use of zoledronic acid in pediatric cancer patients.

  Pediatric blood & cancer 20110401

• Zoledronic acid induces autophagic cell death in human prostate cancer cells.

  The Journal of urology 20110401

• Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.

  Clinical & experimental metastasis 20110401

• Zoledronic acid for prevention and treatment of osteoporosis.

  Expert opinion on pharmacotherapy 20110401

• A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.

  The American journal of gastroenterology 20110401

• Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line.

  Cell proliferation 20110401

• Local treatment of cancellous bone grafts with BMP-7 and zoledronate increases both the bone formation rate and bone density: a bone chamber study in rats.

  Acta orthopaedica 20110401

• Trials define anti-tumor effects of anti-resorptive agents: denosumab ahead of zoledronate 2 to 1.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110401

• Pamidronate and zoledronate effects in the increment of bone mineral density and histomorphometry in rats.

  Acta cirurgica brasileira 20110401

• Osteonecrosis of the jaw.

  Journal of the American Dental Association (1939) 20110401

• More about osteonecrosis.

  Journal of the American Dental Association (1939) 20110401

• [Effects of zoledronic acid in the treatment of breast cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110401

• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110320

• American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110320

• Effect of zoledronate on oral wound healing in rats.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110315

• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  Lancet (London, England) 20110305

• Unravelling the role of denosumab in prostate cancer.

  Lancet (London, England) 20110305

• The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.

  Journal of cellular and molecular medicine 20110301

• Zoledronic acid and atrial fibrillation in cancer patients.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110301

• The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid.

  Cancer chemotherapy and pharmacology 20110301

• Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.

  Oral diseases 20110301

• Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110301

• Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20110301

• Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris.

  International journal of oral and maxillofacial surgery 20110301

• The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.

  Prostate cancer and prostatic diseases 20110301

• Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.

  Naunyn-Schmiedeberg's archives of pharmacology 20110301

• The effects of zoledronic acid on neointimal hyperplasia: a rabbit carotid anastomosis model.

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20110301

• Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study.

  Oral oncology 20110301

• Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20110301

• Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

  European journal of cancer (Oxford, England : 1990) 20110301

• Breast cancer bone metastases: denosumab or zoledronic acid?

  Nature reviews. Endocrinology 20110301

• [Parathyroid crisis due to a cystic parathyroid adenoma].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20110301

• [Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer].

  Clinical calcium 20110301

• [Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].

  Clinical calcium 20110301

• Multiple hydrogen bonds in cytosinium zoledronate trihydrate.

  Acta crystallographica. Section C, Crystal structure communications 20110301

• [A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110301

• Unexpected AZURE results lead to rethink for Zometa(®).

  Expert review of anticancer therapy 20110301

• Zoledronic acid for adjuvant use in patients with breast cancer.

  Expert review of anticancer therapy 20110301

• Direct antitumour activity of zoledronic acid: preclinical and clinical data.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20110301

• Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.

  Clinical therapeutics 20110301

• Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.

  Hiroshima journal of medical sciences 20110301

• 'Disappointing' trial results offer hope for older women with breast cancer.

  JAMA 20110223

• The effects of estrogen deficiency and bisphosphonate treatment on tissue mineralisation and stiffness in an ovine model of osteoporosis.

  Journal of biomechanics 20110203

• Osteonecrosis of the jaw and the role of macrophages.

  Journal of the National Cancer Institute 20110202

• Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.

  Clinical oral investigations 20110201

• Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.

  Internal medicine journal 20110201

• Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201

• Bisphosphonate remains highly localized after elution from porous implants.

  Clinical orthopaedics and related research 20110201

• Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats.

  Head & neck 20110201

• Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: critical influence of the drug introduction mode on the in vitro cement properties.

  Acta biomaterialia 20110201

• Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.

  Bone 20110201

• Effects of short-term zoledronic acid treatment on bone remodeling and healing at surgical sites in the maxilla and mandible of aged dogs.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20110201

• Zoledronate inhibits intimal hyperplasia in balloon-injured rat carotid artery.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20110201

• Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.

  European journal of immunology 20110201

• Development of multiple myeloma in a case of longstanding ankylosing spondylitis: more than a coincidence?

  International journal of rheumatic diseases 20110201

• Gorham-Stout syndrome of the pelvic girdle treated by radiation therapy: a case report.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20110201

• Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.

  Critical reviews in oncology/hematology 20110201

• Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.

  Critical reviews in oncology/hematology 20110201

• Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?

  Critical reviews in oncology/hematology 20110201

• The backbone of progress--preclinical studies and innovations with zoledronic acid.

  Critical reviews in oncology/hematology 20110201

• Anticancer evidence for zoledronic acid across the cancer continuum.

  Critical reviews in oncology/hematology 20110201

• [Study on the effects of zoledronic-acid-loaded collagen membrane on bone metabolism cells].

  Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology 20110201

• Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.

  International journal of pharmaceutics 20110117

• Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases.

  International journal of cancer 20110115

• [Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20110110

• Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines.

  Molecular biology reports 20110101

• Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110101

• Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110101

• Initial results of the treatment of diffuse sclerosing osteomyelitis of the mandible with bisphosphonates.

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20110101

• Treatment and prevention of bone complications from prostate cancer.

  Bone 20110101

• Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110101

• The response of dental pulp-derived cells to zoledronate depends on the experimental model.

  International endodontic journal 20110101

• Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.

  Cytotherapy 20110101

• Skeletal complications and survival in renal cancer patients with bone metastases.

  Bone 20110101

• Combined effects of zoledronate and mechanical stimulation on bone adaptation in an axially loaded mouse tibia.

  Clinical biomechanics (Bristol, Avon) 20110101

• Active Paget's disease of bone with normal biomarkers of bone metabolism: a case report and review of the literature.

  Clinical rheumatology 20110101

• Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).

  Breast cancer research and treatment 20110101

• Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.

  Anti-cancer drugs 20110101

• Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20110101

• The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

  Experimental hematology 20110101

• Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.

  Clinical rheumatology 20110101

• New approaches to the treatment of osteoporosis.

  Annual review of medicine 20110101

• Bone scans, bisphosphonates, and a lack of acute changes within the mandible.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20110101

• Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.

  Thyroid : official journal of the American Thyroid Association 20110101

• Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.

  Current medical research and opinion 20110101

• Zoledronic acid.

  Expert opinion on drug safety 20110101

• Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.

  American journal of hematology 20110101

• Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.

  Frontiers in bioscience (Elite edition) 20110101

• The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands.

  Journal of medical economics 20110101

• Zoledronic acid use in cancer patients: more than just supportive care?

  Cancer 20110101

• Bisphosponates and dental implants: a case report and a brief review of literature.

  Minerva stomatologica 20110101

• The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.

  Clinical lung cancer 20110101

• Two cases of drug-induced orbital inflammatory disease.

  Orbit (Amsterdam, Netherlands) 20110101

• Zoledronic acid treatment in children with osteogenesis imperfecta.

  Hormone research in paediatrics 20110101

• The influence of bisphosphonates on human osteoblast migration and integrin aVb3/tenascin C gene expression in vitro.

  Head & face medicine 20110101

• New strategies to prevent and manage bone complications in cancer.

  Clinical advances in hematology & oncology : H&O 20110101

• What do we know about the ocular adverse effects associated with intravenous bisphosphonates?

  Eklem hastaliklari ve cerrahisi = Joint diseases & related surgery 20110101

• [Bisphosphonate-induced osteonecrosis of the jaw in a patient with metastatic breast cancer].

  Revista espanola de medicina nuclear 20110101

• Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial).

  The journal of supportive oncology 20110101

• Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands.

  Journal of medical economics 20110101

• Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines.

  International journal of immunopathology and pharmacology 20110101

• Supportive therapy in multiple myeloma.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• [Disseminated carcinomatosis of the bone marrow in two patients with prostate cancer].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20110101

• Denosumab an option for patients with bone metastasis from breast cancer.

  CA: a cancer journal for clinicians 20110101

• A case of acquired Fanconi syndrome induced by zoledronic acid.

  Internal medicine (Tokyo, Japan) 20110101

• Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form.

  The journal of supportive oncology 20110101

• Role of zoledronic acid in the prevention and treatment of osteoporosis.

  Clinical interventions in aging 20110101

• Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.

  PloS one 20110101

• Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro.

  BMC musculoskeletal disorders 20110101

• Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects.

  The breast journal 20110101

• Orbital inflammatory disease in a patient treated with zoledronate.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis.

  Journal of experimental & clinical cancer research : CR 20110101

• Transient changes in thyroid functions tests after zoledronic acid infusion.

  Endocrine journal 20110101

• Systemic lupus erythematosus and hypercalcaemia: case report and brief review of the literature.

  Scandinavian journal of rheumatology 20110101

• Expansion of human peripheral blood γδ T cells using zoledronate.

  Journal of visualized experiments : JoVE 20110101

• Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving 'metronomic' zoledronic acid.

  BMC cancer 20110101

• Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies.

  Tumori 20110101

• Going on a drug holiday?

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20110101

• Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients.

  Journal (Canadian Dental Association) 20110101

• [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].

  Urologia 20110101

• Bisphosphonates and breast cancer incidence and recurrence.

  Breast disease 20110101

• Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.

  Breast disease 20110101

• The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.

  Oncology 20110101

• Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic Acid.

  Onkologie 20110101

• A feasibility study of zoledronic acid combined with carboplatin/nedaplatin plus paclitaxel in patients with non-small cell lung cancer with bone metastases.

  Tumori 20110101

• [Innovative approaches to diagnosis and treatment of occupational diseases (on joint diseases model)].

  Meditsina truda i promyshlennaia ekologiia 20110101

• Zoledronic acid and osteonecrosis of the jaw: incidence varies with use.

  General dentistry 20110101

• Survival benefit during zoledronic acid and docetaxel-based chemotherapy in metastatic hormone-refractory prostate cancer patients: an institutional report.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• Primary systemic therapy in breast cancer--an update for gynecologic oncologists.

  European journal of gynaecological oncology 20110101

• Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

  Cancer research 20101215

• Zoledronic acid in myeloma: MRC Myeloma IX.

  Lancet (London, England) 20101211

• Recurrent scrotal hemangiomas during treatment with sunitinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101210

• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101210

• First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.

  Lancet (London, England) 20101202

• Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

  Journal of cellular and molecular medicine 20101201

• Solid-state forms of zoledronic acid: polymorphism in hydrates.

  Journal of pharmaceutical sciences 20101201

• Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.

  British journal of haematology 20101201

• Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.

  Breast cancer research and treatment 20101201

• Effects of zoledronate in the repair of chronically infarcted rat myocardium.

  Journal of cardiovascular pharmacology 20101201

• The effects of topical application of bisphosphonates on replanted rat molars.

  Dental traumatology : official publication of International Association for Dental Traumatology 20101201

• Osteonecrosis of the maxilla associated with the use of bisphosphonates.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20101201

• Bisphosphonate-associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case report.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20101201

• [gammadelta T cells stimulated by zoledronate kill osteosarcoma cells].

  Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20101201

• The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.

  Clinical breast cancer 20101201

• Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.

  Clinical breast cancer 20101201

• Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.

  Clinical breast cancer 20101201

• [Prosthetic rehabilitation after osteonecrosis of the jaws due to histiocytosis X and treatment with bisphosphonates apropos of a case].

  Odonto-stomatologie tropicale = Tropical dental journal 20101201

• Effect of single dose intravenous zoledronic acid on bone mineral density in post-menopausal osteoporosis of Bangladeshi women.

  Bangladesh Medical Research Council bulletin 20101201

• Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20101101

• Beyond bisphosphonates: photodynamic therapy structurally augments metastatically involved vertebrae and destroys tumor tissue.

  Breast cancer research and treatment 20101101

• Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20101101

• Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.

  Journal of bone and mineral metabolism 20101101

• Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.

  Cancer immunology, immunotherapy : CII 20101101

• Molecular interactions between zoledronic acid and bone: An in vitro Raman microspectroscopic study.

  Bone 20101101

• Future directions of bone-targeted therapy for metastatic breast cancer.

  Nature reviews. Clinical oncology 20101101

• Surface immobilized zoledronate improves screw fixation in rat bone: a new method for the coating of metal implants.

  Journal of materials science. Materials in medicine 20101101

• Anticancer properties of zoledronic acid.

  Cancer investigation 20101101

• Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.

  Cancer research 20101101

• Treatment of Gorham-Stout disease with zoledronic acid and interferon-α: a case report and literature review.

  Journal of pediatric hematology/oncology 20101101

• Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20101101

• The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.

  Expert opinion on pharmacotherapy 20101101

• The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.

  Journal of the American Dental Association (1939) 20101101

• Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible.

  Orthodontics & craniofacial research 20101101

• Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.

  The oncologist 20101101

• Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.

  Urology 20101101

• Chronic indurated gingival ulceration. Bisphosphonate-related osteonecrosis of the jaw (BRONJ).

  Archives of dermatology 20101101

• Oxidant and antioxidant activity in rabbit livers treated with zoledronic acid.

  Transplantation proceedings 20101101

• Management of osteonecrosis of the jaws in patients with history of bisphosphonates therapy.

  The Journal of craniofacial surgery 20101101

• Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101015

• A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20101001

• [Maxillary osteonecrosis associated with the use of zoledronate: Presentation of three cases].

  Atencion primaria 20101001

• Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.

  Breast (Edinburgh, Scotland) 20101001

• Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20101001

• Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20101001

• Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease.

  Pediatrics international : official journal of the Japan Pediatric Society 20101001

• The role of zoledronic acid in the management of osteoporosis.

  Clinical rheumatology 20101001

• Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice.

  Calcified tissue international 20101001

• Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.

  Breast cancer research and treatment 20101001

• Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.

  Cancer investigation 20101001

• Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma.

  British journal of haematology 20101001

• Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease.

  Osteoarthritis and cartilage 20101001

• Predicting skeletal complications in metastatic breast cancer raises challenges.

  Breast cancer research and treatment 20101001

• Short-term zoledronic acid reduces trabecular bone remodeling in dogs.

  European journal of oral sciences 20101001

• Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.

  Cancer research 20101001

• Bisphosphonates as anticancer therapy for early breast cancer.

  Clinical breast cancer 20101001

• Zolendronate associated inflammatory orbital disease.

  The New Zealand medical journal 20100924

• Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.

  Cancer biology & therapy 20100915

• Bisphosphonates and atypical femoral fractures.

  The New England journal of medicine 20100909

• Bisphosphonates and atypical femoral fractures.

  The New England journal of medicine 20100909

• Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100901

• Flare-up of hand osteoarthritis caused by zoledronic acid infusion.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100901

• Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100901

• Preparation and preclinical pharmacological study on a novel bone imaging agent (99m)Tc-EMIDP.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20100901

• Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.

  Current opinion in supportive and palliative care 20100901

• Synergistic induction of bone formation by hOP-1, hTGF-beta3 and inhibition by zoledronate in macroporous coral-derived hydroxyapatites.

  Biomaterials 20100901

• Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells.

  Journal of clinical immunology 20100901

• Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100901

• Characterization of and risk factors for the acute-phase response after zoledronic acid.

  The Journal of clinical endocrinology and metabolism 20100901

• Update on the use of zoledronic acid in the management of osteoporosis.

  Current osteoporosis reports 20100901

• Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy.

  Calcified tissue international 20100901

• Updates on osteonecrosis of the jaw.

  Current opinion in supportive and palliative care 20100901

• Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.

  The Annals of pharmacotherapy 20100901

• Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.

  Nature chemical biology 20100901

• [Bisphosphonates in adjuvant therapy of breast cancer].

  Medizinische Klinik (Munich, Germany : 1983) 20100901

• Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid.

  Anticancer research 20100901

• [Preparation of zoledronic-acid-loaded collagen membrane].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100901

• A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro.

  Cancer letters 20100828

• Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.

  British journal of cancer 20100824

• Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.

  Journal of controlled release : official journal of the Controlled Release Society 20100817

• Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100801

• A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat.

  Microscopy research and technique 20100801

• A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.

  International journal of clinical oncology 20100801

• In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

  Clinical and experimental immunology 20100801

• [Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].

  Bulletin du cancer 20100801

• Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.

  Clinical breast cancer 20100801

• Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801

• In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?

  The Journal of the Oklahoma State Medical Association 20100801

• [Effect of zoledronic acid on the differentiation and osteoprotegerin production of osteoblasts in rabbit].

  Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology 20100801

• [Active pharmacosurveillance of patients affiliated to the Colombian general social security/health system].

  Revista de salud publica (Bogota, Colombia) 20100801

• Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.

  International journal of cancer 20100715

• Sterol-regulatory-element-binding protein 2 and nuclear factor Y control human farnesyl diphosphate synthase expression and affect cell proliferation in hepatoblastoma cells.

  The Biochemical journal 20100715

• Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100701

• Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100701

• Response to zolendronic acid in children with type III osteogenesis imperfecta.

  Journal of bone and mineral metabolism 20100701

• Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100701

• Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20100701

• Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.

  The American journal of pathology 20100701

• Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100701

• Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.

  Oncology reports 20100701

• Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100701

• Bisphosphonates for bone pain #113.

  Journal of palliative medicine 20100701

• [Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• Combined effects of bisphosphonate and radiation on osteosarcoma cells.

  Anticancer research 20100701

• Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.

  Clinical advances in hematology & oncology : H&O 20100701

• Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.

  Cancer research 20100615

• Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100615

• Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20100601

• Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.

  Clinical oral investigations 20100601

• Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.

  Clinical oral investigations 20100601

• Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100601

• Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100601

• Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats.

  Calcified tissue international 20100601

• [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].

  Clinical calcium 20100601

• Zoledronate complexes. III. Two zoledronate complexes with alkaline earth metals: [Mg(C(5)H(9)N(2)O(7)P(2))(2)(H(2)O)(2)] and [Ca(C(5)H(8)N(2)O(7)P(2))(H(2)O)](n).

  Acta crystallographica. Section C, Crystal structure communications 20100601

• Postmenopausal osteoporosis: another approach to management.

  The Journal of family practice 20100601

• Long term zoledronic acid during androgen blockade for prostate cancer.

  The Canadian journal of urology 20100601

• [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100601

• The evolving role of bone-conserving therapy in patients with breast cancer.

  Seminars in oncology 20100601

• Therapeutic options in the management of myeloma bone disease.

  Seminars in oncology 20100601

• Maintaining bone health in prostate cancer throughout the disease continuum.

  Seminars in oncology 20100601

• Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.

  Seminars in oncology 20100601

• Bisphosphonates in lung cancer: more than a palliative therapy?

  Seminars in oncology 20100601

• Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

  The New England journal of medicine 20100513

• Evolving data about subtrochanteric fractures and bisphosphonates.

  The New England journal of medicine 20100513

• Evidence of drug confinement into silica mesoporous matrices by STEM spherical aberration corrected microscopy.

  Chemical communications (Cambridge, England) 20100507

• An in vitro assay to measure targeted drug delivery to bone mineral.

  ChemMedChem 20100503

• Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series.

  Cancer chemotherapy and pharmacology 20100501

• Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.

  Journal of bone and mineral metabolism 20100501

• Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100501

• Additive effects of estrogen replacement therapy and bisphosphonates on osseointegration of hydroxyapatite-coated titanium screws in ovariectomized rats.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20100501

• Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100501

• A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20100501

• Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20100501

• The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.

  Urology 20100501

• Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

  The Lancet. Oncology 20100501

• Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.

  Leukemia 20100501

• Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.

  Translational research : the journal of laboratory and clinical medicine 20100501

• Editorial comment.

  Urology 20100501

• [A case report of a patient treatable by home palliative care, administered zoledronic acid used for bladder cancer with hypercalcemia].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100501

• Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.

  Anticancer research 20100501

• [Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20100501

• [Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon DU145 prostate cancer cells].

  Zhonghua yi xue za zhi 20100413

• Zoledronate reduces unwanted bone resorption in intercalary bone allografts.

  International orthopaedics 20100401

• Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.

  Cancer chemotherapy and pharmacology 20100401

• Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.

  BJU international 20100401

• Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.

  Journal of endocrinological investigation 20100401

• Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.

  Breast (Edinburgh, Scotland) 20100401

• Exercise and zoledronic acid on lipid profile and bone remodeling in ovariectomized rats: a paradoxical negative association?

  Lipids 20100401

• Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100401

• Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss.

  Nature reviews. Clinical oncology 20100401

• [Primary hyperparathyroidism in a patient with Paget's bone disease].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20100401

• Bisphosphonates in adjuvant treatment of early breast cancer.

  Critical reviews in oncology/hematology 20100401

• Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.

  Critical reviews in oncology/hematology 20100401

• The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ..

  Critical reviews in oncology/hematology 20100401

• Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20100401

• Generalized melanosis and melanuria in a patient with metastatic melanoma.

  Clinical and experimental dermatology 20100401

• Health trends.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100401

• Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.

  Prescrire international 20100401

• The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.

  British journal of cancer 20100330

• Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.

  British journal of cancer 20100316

• V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.

  Journal of immunology (Baltimore, Md. : 1950) 20100315

• Case 36-2009: A man with cough, hoarseness, and abnormalities on chest imaging.

  The New England journal of medicine 20100311

• Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20100301

• Improving bone density at the rotator cuff footprint increases supraspinatus tendon failure stress in a rat model.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20100301

• The effect of soaking allograft in bisphosphonate: a pilot dose-response study.

  Clinical orthopaedics and related research 20100301

• Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.

  Biochemical pharmacology 20100301

• Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice.

  Journal of bone and mineral metabolism 20100301

• No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site.

  Bone 20100301

• Bone health and prostate cancer.

  Prostate cancer and prostatic diseases 20100301

• A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients.

  Bone 20100301

• Jaw bone changes in rats after treatment with zoledronate and pamidronate.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20100301

• Use of zoledronic acid in the treatment of Gorham's disease.

  International journal of pediatric otorhinolaryngology 20100301

• Effect of osteoporosis treatment on mortality: a meta-analysis.

  The Journal of clinical endocrinology and metabolism 20100301

• Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.

  Journal of medical economics 20100301

• Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.

  Oral oncology 20100301

• The effect of zoledronate during bone healing.

  Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20100301

• Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100301

• [Assessment and treatment of osteoporotic hip fractures].

  Ugeskrift for laeger 20100301

• [Difference in treatment for metastatic bone tumors due to differences in opinion among departments--the role of medical teams for metastatic bone tumors].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100301

• Bone disease in prostate cancer.

  Asia-Pacific journal of clinical oncology 20100301

• Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.

  Clinical therapeutics 20100301

• Intravenous zoledronic acid: what are the indications for male osteoporosis?

  Current osteoporosis reports 20100301

• Glucocorticoid-induced osteoporosis: management update.

  Current osteoporosis reports 20100301

• FDA drug information that never reaches clinicians.

  The New England journal of medicine 20100211

• Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.

  American journal of clinical oncology 20100201

• The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study.

  Bone 20100201

• Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.

  The Journal of clinical endocrinology and metabolism 20100201

• Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.

  Journal of the American Geriatrics Society 20100201

• Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.

  Current cancer drug targets 20100201

• [Bone and Men's Health. Bisphosphonate therapy for prostate cancer].

  Clinical calcium 20100201

• Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.

  Clinical breast cancer 20100201

• Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.

  Anticancer research 20100201

• Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.

  International journal of cancer 20100115

• Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells.

  The Journal of biological chemistry 20100115

• Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100101

• Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells.

  Cancer letters 20100101

• Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100101

• Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100101

• The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.

  International journal of cancer 20100101

• Non-persistent effect of short-term bisphosphonate treatment in preventing fractures after liver transplantation.

  Transplant international : official journal of the European Society for Organ Transplantation 20100101

• Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.

  Bone 20100101

• Differences between bisphosphonates in binding affinities for hydroxyapatite.

  Journal of biomedical materials research. Part B, Applied biomaterials 20100101

• Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.

  European journal of cancer (Oxford, England : 1990) 20100101

• Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.

  Lung cancer (Amsterdam, Netherlands) 20100101

• Is zoledronate toxic to human periodontal fibroblasts?

  Journal of dental research 20100101

• Dysuria caused by pelvic metastasis from breast carcinoma was alleviated by multi-modality therapy with zoledronic acid.

  The breast journal 20100101

• Zoledronic acid: an unending tale for an antiresorptive agent.

  Expert opinion on pharmacotherapy 20100101

• IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.

  Pathology 20100101

• Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis.

  Joint, bone, spine : revue du rhumatisme 20100101

• Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines.

  The Journal of bone and joint surgery. American volume 20100101

• A clinico-pathologic correlation. Bisphosphonate-related osteonecrosis of the jaws.

  Journal of the Massachusetts Dental Society 20100101

• Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20100101

• Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.

  Biological & pharmaceutical bulletin 20100101

• Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?

  Current oncology reports 20100101

• Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?

  Journal of vascular research 20100101

• Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.

  Journal of cancer research and therapeutics 20100101

• Zoledronic acid treatment of osteoporosis: effects in men.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101

• [Effects of zoledronic acid in adults with osteogenesis imperfecta].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20100101

• Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.

  Onkologie 20100101

• Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101

• The impact of bisphosphonates on the osteoblast proliferation and Collagen gene expression in vitro.

  Head & face medicine 20100101

• Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.

  Urologia internationalis 20100101

• Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.

  Onkologie 20100101

• Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer.

  Journal of experimental & clinical cancer research : CR 20100101

• Zoledronate stimulates gamma delta T cells in prostate cancer patients.

  Oncology research 20100101

• Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.

  BMC cancer 20100101

• Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma.

  Molecular cancer 20100101

• [Effect of a single dose of zoledronic acid in a case of Paget bone disease].

  Medicina 20100101

• [Zoledronic acid reduces risk of any new clinical fracture and risk of death after surgical repair of a low-trauma hip fracture].

  Chirurgia narzadow ruchu i ortopedia polska 20100101

• Women and bone health: maximizing the benefits of aromatase inhibitor therapy.

  Oncology 20100101

• Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.

  General dentistry 20100101

• Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.

  Cancer immunity 20100101

• Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.

  Bulletin de la Societe belge d'ophtalmologie 20100101

• Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid.

  Hormones (Athens, Greece) 20100101

• Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

  Drug design, development and therapy 20100101

• Effect of zoledronic acid used in the root surface treatment of late replanted teeth: a study in rats.

  Brazilian dental journal 20100101

• Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures.

  Clinical and experimental rheumatology 20100101

• The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.

  PloS one 20100101

• Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series.

  Minerva stomatologica 20100101

• Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review.

  The Laryngoscope 20100101

• Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.

  Nucleus (Austin, Tex.) 20100101

• Zoledronic acid in metastatic bone disease: an audit based discussion.

  Journal of Ayub Medical College, Abbottabad : JAMC 20100101

• Bisphosphonate-related osteonecrosis of the jaw and left thumb.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091210

• Aminobisphosphonate stimulates bone regeneration and enforces consolidation of titanium implant into a new rat caudal vertebrae model.

  Pathology oncology research : POR 20091201

• A novel bioassay model to determine clinically significant bisphosphonate levels.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20091201

• The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.

  Bone 20091201

• Bone morphogenetic proteins and zoledronic acid.

  Annals of oncology : official journal of the European Society for Medical Oncology 20091201

• The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer.

  European journal of cancer (Oxford, England : 1990) 20091201

• Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.

  Cancer investigation 20091201

• Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.

  BJU international 20091201

• [New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• A rare case of Paget's disease of the bone in the Philippines.

  International journal of rheumatic diseases 20091201

• Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110

• Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease.

  Bone 20091101

• Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.

  International journal of cancer 20091101

• The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20091101

• Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination.

  Cell biology international 20091101

• Bisphosphonates in breast cancer: teaching an old dog new tricks.

  Current opinion in oncology 20091101

• Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.

  The Journal of urology 20091101

• A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.

  Japanese journal of clinical oncology 20091101

• Locally delivered bisphosphonate for enhancement of bone formation and implant fixation.

  The Journal of bone and joint surgery. American volume 20091101

• Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.

  Current cancer drug targets 20091101

• Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.

  Obstetrics and gynecology 20091101

• [Management of serum calcium with cinacelet in parathyroid cancer].

  Ugeskrift for laeger 20091005

• Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.

  Journal of biomedical materials research. Part A 20091001

• Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.

  Breast cancer research and treatment 20091001

• The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

  International journal of cancer 20091001

• Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient.

  Annals of oncology : official journal of the European Society for Medical Oncology 20091001

• Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20091001

• Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

  Molecular cancer therapeutics 20091001

• Bifocal sarcomatous transformation of Paget's disease: a case report.

  Joint, bone, spine : revue du rhumatisme 20091001

• Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.

  International journal of clinical oncology 20091001

• Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.

  Cancer biotherapy & radiopharmaceuticals 20091001

• High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090915

• Superparamagnetic nanovector with anti-cancer properties: gamma Fe2O3@Zoledronate.

  International journal of pharmaceutics 20090911

• Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach.

  Head & neck 20090901

• Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090901

• Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.

  Medical hypotheses 20090901

• Zoledronic acid may be a treatment option for hyperparathyroidism.

  Medical hypotheses 20090901

• Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon.

  Transfusion 20090901

• The rabbit biodistribution of a therapeutic dose of zoledronic acid labeled with Tc-99m.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20090901

• Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells.

  European journal of clinical investigation 20090901

• Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

  The Journal of clinical endocrinology and metabolism 20090901

• Zoledronic acid decreases bone formation without causing osteocyte death in mice.

  Archives of oral biology 20090901

• A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.

  The Annals of pharmacotherapy 20090901

• New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab.

  Current osteoporosis reports 20090901

• Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.

  Expert review of anticancer therapy 20090901

• Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.

  International journal of urology : official journal of the Japanese Urological Association 20090901

• Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.

  International journal of urology : official journal of the Japanese Urological Association 20090901

• [Antitumor activity of zoledronic acid].

  Magyar onkologia 20090901

• Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells.

  European cytokine network 20090901

• Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.

  Reviews on recent clinical trials 20090901

• Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090801

• Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

  Experimental hematology 20090801

• [Osteonecrosis of the jaw].

  La Revue de medecine interne 20090801

• Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.

  Cancer 20090801

• Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer.

  Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 20090801

• Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats?

  Calcified tissue international 20090801

• [Numb chin syndrome caused by biphosphonates-induced osteonecrosis of the jaw].

  Revista de neurologia 20090801

• Mandibular necrosis in beagle dogs treated with bisphosphonates.

  Orthodontics & craniofacial research 20090801

• Multimodal therapy for vertebral involvement of systemic mastocytosis.

  Spine 20090801

• The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.

  Mini reviews in medicinal chemistry 20090801

• Corticosteroids: no drug prevention of fractures needed.

  Prescrire international 20090801

• Zolendronate in osteogenesis imperfecta.

  Journal of pediatric endocrinology & metabolism : JPEM 20090801

• Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells.

  Biochemical pharmacology 20090715

• Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.

  Bone marrow transplantation 20090701

• Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090701

• Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701

• Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.

  Experimental hematology 20090701

• Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?

  European journal of cancer (Oxford, England : 1990) 20090701

• Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20090701

• Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined.

  Journal of palliative medicine 20090701

• Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.

  Clinical lung cancer 20090701

• Effect of locally administered zoledronic acid on injury-induced intramembranous bone regeneration and osseointegration of a titanium implant in rats.

  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20090701

• Comparison of phenotype of gammadelta T cells generated using various cultivation methods.

  Immunology letters 20090630

• Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.

  The Medical letter on drugs and therapeutics 20090629

• Prediction of bone density around orthopedic implants delivering bisphosphonate.

  Journal of biomechanics 20090619

• Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.

  Cancer letters 20090608

• Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).

  Clinical endocrinology 20090601

• Comment on: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.

  Oral oncology 20090601

• Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20090601

• Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy.

  Clinical immunology (Orlando, Fla.) 20090601

• Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.

  British journal of pharmacology 20090601

• Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.

  The American journal of pathology 20090601

• Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion.

  Melanoma research 20090601

• Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20090601

• Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.

  Journal of immunology (Baltimore, Md. : 1950) 20090601

• [The role of oncology nurses in treatment outcomes. What can we do for the patients' compliance treated with intravenous zoledronic acid?].

  Magyar onkologia 20090601

• Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.

  Cancer biology & therapy 20090601

• [Zoledronic acid blocks cell cycle and induces apoptosis in lung cancer cell line 95D cells and their mechanisms of action].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090601

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090528

• Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090515

• Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.

  The Prostate 20090501

• Hyperparathyroidism secondary to zoledronic acid infusion: case report.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20090501

• Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20090501

• Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.

  Journal of clinical pathology 20090501

• Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

  Haematologica 20090501

• High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.

  The oncologist 20090501

• Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

  Clinical breast cancer 20090501

• Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation.

  Bone 20090501

• The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

  Bone 20090501

• Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.

  Clinical therapeutics 20090501

• Glucocorticoid-induced osteoporosis: hope on the HORIZON.

  Lancet (London, England) 20090411

• Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

  Lancet (London, England) 20090411

• Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro.

  Journal of biomedical materials research. Part A 20090401

• Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.

  Cancer immunology, immunotherapy : CII 20090401

• Re: Christian Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.

  European urology 20090401

• Bone structure and remodelling in stroke patients: early effects of zoledronate.

  Bone 20090401

• Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20090401

• Zoledronic acid-induced regression of multiple metastases at nonskeletal sites.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090401

• Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20090401

• Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer.

  Nature reviews. Clinical oncology 20090401

• Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.

  Anticancer research 20090401

• Paget's disease of bone and osteonecrosis.

  Dental update 20090401

• Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.

  AIDS (London, England) 20090313

• Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.

  JOP : Journal of the pancreas 20090309

• [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].

  MMW Fortschritte der Medizin 20090305

• Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.

  European urology 20090301

• Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.

  BJU international 20090301

• Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.

  British journal of haematology 20090301

• Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20090301

• The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats.

  Biomaterials 20090301

• Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.

  Gynecologic oncology 20090301

• Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?

  Annals of oncology : official journal of the European Society for Medical Oncology 20090301

• Effect of bisphosphonates on pain and quality of life in patients with bone metastases.

  Nature clinical practice. Oncology 20090301

• Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy.

  International journal of molecular medicine 20090301

• The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20090301

• Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20090301

• Bisphosphonate-related osteonecrosis of the skull base.

  The Laryngoscope 20090301

• [Once-yearly administration of zoledronic acid to treat post-menopausal osteoporosis].

  Der Unfallchirurg 20090301

• [A case of bone marrow carcinosis from gastric cancer that presented hypocalcemia caused by zoledronic acid during the treatment of methotrexate/5-fluorouracil sequential therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090301

• Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.

  Hiroshima journal of medical sciences 20090301

• [Primary hyperparathyroidism. An alternative to the surgery].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20090301

• [Effect of zoledronic acid on the growth and CD138 expression of myeloma cell line KM3].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090301

• Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.

  Cancer letters 20090218

• Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

  The New England journal of medicine 20090212

• Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.

  Oral oncology 20090201

• Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.

  BJU international 20090201

• Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20090201

• Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.

  Bone 20090201

• The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.

  The Journal of clinical endocrinology and metabolism 20090201

• Effect of combined local treatment with zoledronic acid and basic fibroblast growth factor on implant fixation in ovariectomized rats.

  Bone 20090201

• Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.

  Cell biology international 20090201

• Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090201

• Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series.

  The Laryngoscope 20090201

• The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial.

  The Journal of bone and joint surgery. American volume 20090201

• [Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta].

  Clinical calcium 20090201

• Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

  The American journal of medicine 20090201

• Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells.

  European journal of pharmacology 20090105

• [Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].

  Ugeskrift for laeger 20090105

• A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.

  AIDS (London, England) 20090102

• In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.

  Cancer immunology, immunotherapy : CII 20090101

• Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.

  Medical oncology (Northwood, London, England) 20090101

• Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090101

• Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation.

  The Journal of surgical research 20090101

• Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.

  The British journal of oral & maxillofacial surgery 20090101

• Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090101

• Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090101

• Zoledronic acid for the treatment of appendicular osteosarcoma in a dog.

  The Journal of small animal practice 20090101

• Complexes of low energy beta emitters 47Sc and 177Lu with zoledronic acid for bone pain therapy.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20090101

• Inhibition of osteoblast function in vitro by aminobisphosphonates.

  Journal of cellular biochemistry 20090101

• Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

  British journal of haematology 20090101

• Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.

  Journal of bone and mineral metabolism 20090101

• Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20090101

• Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.

  Scandinavian journal of urology and nephrology 20090101

• Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release.

  Journal of immunology (Baltimore, Md. : 1950) 20090101

• San Antonio Breast Cancer Symposium.

  The Lancet. Oncology 20090101

• [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].

  Clinical calcium 20090101

• Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.

  Molecular cancer therapeutics 20090101

• Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports.

  Journal of experimental & clinical cancer research : CR 20090101

• [A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090101

• Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid.

  Archives of dermatology 20090101

• New bisphosphonates and trends in drug therapy for osteoporosis: preface.

  Clinical calcium 20090101

• Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.

  BMC cancer 20090101

• Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.

  Journal of bone and mineral metabolism 20090101

• Effect of zoledronic acid on bone pain secondary to metastatic bone disease.

  Medicine and health, Rhode Island 20090101

• Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.

  Clinical & experimental metastasis 20090101

• Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.

  Journal of pediatric endocrinology & metabolism : JPEM 20090101

• Multiple myeloma with paraneoplastic leucocytoclastic vasculitis.

  Indian journal of cancer 20090101

• Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings.

  Journal of computer assisted tomography 20090101

• [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].

  Reumatismo 20090101

• [Comparison of two formulae for the calculation of glomerular filtration in the dosage of zoledronic acid].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• What is your diagnosis? Osteonecrosis of the jaw; unknown cause(s).

  Northwest dentistry 20090101

• Once-yearly zoledronic acid in hip fracture prevention.

  Clinical interventions in aging 20090101

• Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.

  The journal of supportive oncology 20090101

• Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

  Trials 20090101

• Residual (ghost) sockets in bisphosphonate use--evidence of poor healing and slow bone turnover.

  General dentistry 20090101

• Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells.

  Immunopharmacology and immunotoxicology 20090101

• Zoledronic acid induced osteonecrosis of tibia and femur.

  Indian journal of cancer 20090101

• Anterior uveitis complicating zoledronic acid infusion.

  Ocular immunology and inflammation 20090101

• [Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma].

  Nihon Jinzo Gakkai shi 20090101

• Management of osteoporosis in the aging male: focus on zoledronic acid.

  Clinical interventions in aging 20090101

• A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.

  Oncology research 20090101

• Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.

  American journal of otolaryngology 20090101

• A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.

  Arthritis research & therapy 20090101

• Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.

  Breast cancer research : BCR 20090101

• Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?

  Breast cancer research : BCR 20090101

• Avascular osteonecrosis of the mandible following bisphosphonate therapy.

  American journal of therapeutics 20090101

• Clinical characterization might help in preventing osteonecrosis of the jaw.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081215

• Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.

  European journal of pharmacology 20081214

• Bisphosphonate nephrotoxicity.

  Kidney international 20081201

• Bisphosphonates in children with hypercalciuria and reduced bone mineral density.

  Pediatric nephrology (Berlin, Germany) 20081201

• Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates.

  Journal of surgical oncology 20081201

• Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20081201

• Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

  The Lancet. Oncology 20081201

• Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer.

  The Journal of rheumatology 20081201

• Annual zoledronic acid for osteoporosis.

  Drug and therapeutics bulletin 20081201

• A classical presentation of Paget disease of bone.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20081201

• Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.

  Oral oncology 20081101

• Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis.

  Annals of hematology 20081101

• Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20081101

• Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

  European urology 20081101

• Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20081101

• Radiology quiz case. Osteonecrosis of the jaw: aminobisphosphonate epidemic.

  Archives of otolaryngology--head & neck surgery 20081101

• [Bisphosphonates for osseus invasion caused by bronchial carcinoma].

  Deutsche medizinische Wochenschrift (1946) 20081101

• Bisphosphonates: a once-yearly treatment option with Reclast.

  South Dakota medicine : the journal of the South Dakota State Medical Association 20081101

• Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010

• Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.

  Cancer immunology, immunotherapy : CII 20081001

• Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20081001

• Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001

• Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.

  Bone 20081001

• Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid.

  European journal of clinical pharmacology 20081001

• Biodistribution and plasma protein binding of zoledronic acid.

  Drug metabolism and disposition: the biological fate of chemicals 20081001

• A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

  Cancer 20081001

• Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

  Haematologica 20081001

• STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20081001

• Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

• Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite.

  The Journal of bone and joint surgery. American volume 20081001

• [Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].

  Clinical calcium 20081001

• Local application of zoledronic acid incorporated in a poly(D,L-lactide)-coated implant accelerates fracture healing in rats.

  Acta orthopaedica 20081001

• A tale of three diseases of the bone.

  Singapore medical journal 20081001

• Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20081001

• Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature.

  Journal of palliative medicine 20081001

• Zoledronic acid infusion and orbital inflammatory disease.

  The New England journal of medicine 20080925

• Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.

  Cancer 20080915

• Manipulating the anabolic and catabolic response in bone graft remodeling: synergism by a combination of local BMP-7 and a single systemic dosis of zoledronate.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20080901

• Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.

  Kidney international 20080901

• Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.

  Oncology reports 20080901

• Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.

  Kidney international 20080901

• Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation.

  Calcified tissue international 20080901

• Influence of early and late zoledronic acid administration on vertebral structure and strength in ovariectomized rats.

  Calcified tissue international 20080901

• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

  The Lancet. Oncology 20080901

• Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.

  Current osteoporosis reports 20080901

• The effect of zoledronic acid on the intrinsic material properties of healing bone: an indentation study.

  Medical engineering & physics 20080901

• [Update on treatment of postmenopausal osteoporosis].

  Revue medicale de Bruxelles 20080901

• Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.

  Clinical interventions in aging 20080901

• Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

  Journal of the National Cancer Institute 20080820

• Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid.

  Internal medicine journal 20080801

• Impact of skeletal complications on patients' quality of life, mobility, and functional independence.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20080801

• Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080801

• [Zoledronic acid for preventing fractures].

  Der Internist 20080801

• Maximizing effectiveness of bisphosphonate therapy for osteoporosis.

  Southern medical journal 20080801

• Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20080801

• Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity: a novel molecular mechanism.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080801

• [Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].

  Clinical calcium 20080801

• Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.

  The oncologist 20080801

• Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study.

  European cells & materials 20080731

• New treatment strategies provide more options for patients with breast cancer.

  JAMA 20080723

• Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080715

• Zoledronic acid is effective against experimental malignant pleural effusion.

  American journal of respiratory and critical care medicine 20080701

• Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.

  Cancer 20080701

• Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.

  The Prostate 20080701

• The effects of bisphosphonates on osteoblasts in vitro.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20080701

• Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

  The Annals of pharmacotherapy 20080701

• High-content assay to study protein prenylation.

  Journal of biomolecular screening 20080701

• Malignant pleural effusions: fixing the leaky faucet.

  American journal of respiratory and critical care medicine 20080701

• Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20080701

• Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging.

  Nature medicine 20080701

• Rejuvenating premature aging.

  Nature medicine 20080701

• [A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080701

• [Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20080701

• [Clinical analysis of therapeutic effect of zoledronic acid combined with radiotherapy for metastatic bone cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20080701

• Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro.

  Journal of biomedical materials research. Part A 20080615

• Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.

  British journal of cancer 20080603

• Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?

  Clinical endocrinology 20080601

• Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.

  Toxicology in vitro : an international journal published in association with BIBRA 20080601

• Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype.

  Cancer chemotherapy and pharmacology 20080601

• RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.

  The Prostate 20080601

• The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis.

  Apoptosis : an international journal on programmed cell death 20080601

• Paget's disease and bisphosphonate-associated osteonecrosis of the jaws.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20080601

• Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.

  International journal of urology : official journal of the Japanese Urological Association 20080601

• Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.

  Journal of cellular and molecular medicine 20080601

• Pulmonary strongyloidiasis mimicking cancer symptoms: a case of hyperinfection in a patient with metastatic lung cancer.

  American journal of clinical oncology 20080601

• [Treatment of multiple angiomatosis involving the skeleton and the abdominal and thoracic cavities with interferon alpha, thalidomide and zoledronate].

  Vnitrni lekarstvi 20080601

• Caspase-2 is required for cell death induced by cytoskeletal disruption.

  Oncogene 20080529

• Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20080501

• Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis.

  Rheumatology (Oxford, England) 20080501

• Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.

  Bone 20080501

• Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20080501

• Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.

  Bioorganic & medicinal chemistry letters 20080501

• A once-yearly IV bisphosphonate for osteoporosis.

  Obstetrics and gynecology 20080501

• Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080501

• Single annual injectable treatment for postmenopausal osteoporosis.

  Expert opinion on drug delivery 20080501

• Use of intravenous bisphosphonates in older women with breast cancer.

  The oncologist 20080501

• Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

  The oncologist 20080501

• [Effectiveness and tolerability of zoledronic acid in the treatment of metastatic prostate cancer].

  Actas urologicas espanolas 20080501

• Hypertrophic osteoarthropathy effectively treated with zoledronic acid.

  Clinical lung cancer 20080501

• New research findings on zoledronic acid: survival, pain, and anti-tumour effects.

  Cancer treatment reviews 20080401

• Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20080401

• Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.

  European journal of nuclear medicine and molecular imaging 20080401

• How effective is bisphosphonate treatment for preventing bone fractures after liver transplantation?

  Nature clinical practice. Gastroenterology & hepatology 20080401

• [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].

  Der Internist 20080401

• Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20080401

• Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.

  Expert opinion on pharmacotherapy 20080401

• [Bony lesion with prostate cancer].

  Clinical calcium 20080401

• Osteonecrosis of the jaw.

  Journal of the American Dental Association (1939) 20080401

• Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080401

• The effects of zoledronic acid on serum lipids in multiple myeloma patients.

  Calcified tissue international 20080401

• Bisphosphonates and osteonecrosis of the jaw: a case report.

  Clinics (Sao Paulo, Brazil) 20080401

• Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.

  Anti-cancer drugs 20080401

• Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.

  Clinical lymphoma & myeloma 20080401

• Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw.

  The New England journal of medicine 20080320

• Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer.

  The Medical journal of Australia 20080317

• [Osteoporosis--new therapeutic possibilities. The Danish Bone Society].

  Ugeskrift for laeger 20080317

• Multicentric reticulohistiocytosis: a systemic osteoclastic disease?

  Arthritis and rheumatism 20080315

• Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation.

  Journal of leukocyte biology 20080301

• Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis.

  Journal of surgical oncology 20080301

• Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse.

  Journal of applied physiology (Bethesda, Md. : 1985) 20080301

• Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

  Cancer 20080301

• A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.

  Current medical research and opinion 20080301

• 'Bis-phossy jaws' - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20080301

• [Jaw fistulas in 75 years-old woman].

  Revista clinica espanola 20080301

• Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20080301

• Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.

  Calcified tissue international 20080301

• Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080301

• Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells.

  Cancer cell 20080301

• [Osteonecrosis of the jaw developing during bisphosphonate treatment].

  Magyar onkologia 20080301

• Intravenous zoledronic acid for the treatment of osteoporosis.

  Current osteoporosis reports 20080301

• Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.

  Quintessence international (Berlin, Germany : 1985) 20080301

• [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20080301

• Zoledronate, fractures, and mortality after hip fracture.

  The New England journal of medicine 20080227

• Zoledronate, fractures, and mortality after hip fracture.

  The New England journal of medicine 20080227

• Zoledronate, fractures, and mortality after hip fracture.

  The New England journal of medicine 20080227

• Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.

  International journal of cancer 20080215

• Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20080201

• Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080201

• Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).

  Investigational new drugs 20080201

• Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.

  Lung cancer (Amsterdam, Netherlands) 20080201

• [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].

  Deutsche medizinische Wochenschrift (1946) 20080201

• Reply to the article 'oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases' by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).

  Annals of oncology : official journal of the European Society for Medical Oncology 20080201

• Acute adrenal crisis and hypercalcemia in a patient assuming high liquorice doses.

  Minerva medica 20080201

• Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.

  The oncologist 20080201

• Osteonecrosis of the jaw.

  Oncology (Williston Park, N.Y.) 20080201

• [Prescription of bisphosphonates in prostate cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080201

• NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.

  Journal of the American Chemical Society 20080130

• Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20080101

• Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20080101

• The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.

  Acta oncologica (Stockholm, Sweden) 20080101

• Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.

  Joint, bone, spine : revue du rhumatisme 20080101

• Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible?

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20080101

• Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.

  Journal of plastic, reconstructive & aesthetic surgery : JPRAS 20080101

• Zoledronate-related osteonecrosis of the mandible.

  Clinical nuclear medicine 20080101

• Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

  Journal of the American Dental Association (1939) 20080101

• Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.

  Medicina oral, patologia oral y cirugia bucal 20080101

• Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.

  Breast cancer research : BCR 20080101

• Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20080101

• Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.

  Medical oncology (Northwood, London, England) 20080101

• Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.

  Medical oncology (Northwood, London, England) 20080101

• Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.

  Acta haematologica 20080101

• Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

  PharmacoEconomics 20080101

• In vivo and in vitro efficacy of zoledronate for treating oral squamous cell carcinoma in cats.

  Journal of veterinary internal medicine 20080101

• Zoledronic acid : a review of its use in the management of bone metastases of malignancy.

  Drugs 20080101

• The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis.

  Journal of veterinary internal medicine 20080101

• Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.

  BMC clinical pharmacology 20080101

• Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.

  Anticancer research 20080101

• [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].

  Recenti progressi in medicina 20080101

• A case report: zoledronic acid-induced anterior uveitis.

  Medical oncology (Northwood, London, England) 20080101

• Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.

  Anticancer research 20080101

• Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.

  The Journal of international medical research 20080101

• Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.

  Urologia internationalis 20080101

• A once-a-year intravenous treatment of osteoporosis in postmenopausal women: implications for the clinical nurse specialist.

  Clinical nurse specialist CNS 20080101

• Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines.

  International braz j urol : official journal of the Brazilian Society of Urology 20080101

• Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.

  Journal of postgraduate medicine 20080101

• The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis.

  Anticancer research 20080101

• Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment.

  Journal of cancer research and therapeutics 20080101

• Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.

  Journal of translational medicine 20080101

• Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080101

• A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20080101

• Are new-generation bisphosphonates effective for the inhibition of calcium oxalate stone formation in a rat model?

  Urologia internationalis 20080101

• Zoledronic acid: a review of its use in the treatment of osteoporosis.

  Drugs & aging 20080101

• Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.

  Journal of bone and mineral metabolism 20080101

• Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.

  Cytotherapy 20080101

• Zoledronic acid: a review of its use in breast cancer.

  Drugs 20080101

• A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.

  Yonsei medical journal 20071231

• Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro.

  Journal of biomedical materials research. Part A 20071215

• A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid.

  Skeletal radiology 20071201

• [Osteoporosis and bisphosphonates].

  Zeitschrift fur Rheumatologie 20071201

• On the horizon: can bisphosphonates prevent bone metastases?

  Breast (Edinburgh, Scotland) 20071201

• Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid.

  Journal of clinical pharmacy and therapeutics 20071201

• Reducing the risk of bone loss associated with breast cancer treatment.

  Breast (Edinburgh, Scotland) 20071201

• Death of a clinical trial: a speculative inclusion criterion gone wrong.

  Internal medicine journal 20071201

• Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.

  Breast (Edinburgh, Scotland) 20071201

• Reclast approved for osteoporosis treatment in postmenopausal women.

  The Nurse practitioner 20071201

• Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.

  Cancer research 20071201

• [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].

  Clinical calcium 20071201

• Emerging strategies in bone health management for the adjuvant patient.

  Seminars in oncology 20071201

• Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.

  Seminars in oncology 20071201

• Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma.

  Molecular cancer therapeutics 20071201

• Zoledronic acid inhibits osteosarcoma growth in an orthotopic model.

  Molecular cancer therapeutics 20071201

• Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration.

  Journal of palliative medicine 20071201

• Zoledronic acid for Paget's disease of bone.

  Drugs of today (Barcelona, Spain : 1998) 20071201

• Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture.

  The American journal of geriatric pharmacotherapy 20071201

• [Androgen-independent prostate cancer with bone metastasis successfully treated by intravenous administration of zoledronic acid and diethylstilbestrol diphosphate].

  Hinyokika kiyo. Acta urologica Japonica 20071201

• Consultation corner. Bone loss drug gives users a break.

  The Johns Hopkins medical letter health after 50 20071201

• Paget disease of the spine manifested by thoracic and lumbar epidural lipomatosis: magnetic resonance imaging findings.

  Spine 20071201

• Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.

  Clinical breast cancer 20071201

• New annual osteoporosis drug reduces risk of death, future fractures. Infused dose is more convenient for patients, enhances overall quality of life.

  DukeMedicine healthnews 20071201

• Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.

  Head and neck pathology 20071201

• Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.

  Head and neck pathology 20071201

• [Clinical study of bisphosphonates for bone metastasis in breast cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [New bone density conservation agents for osteoporosis under research and development: Zoledronate].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• Zoledronic acid and angiogenesis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071115

• Non-inferiority trial design for recurrent events.

  Statistics in medicine 20071110

• A once-yearly IV bisphosphonate for osteoporosis.

  The Medical letter on drugs and therapeutics 20071105

• Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.

  European urology 20071101

• Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20071101

• Zoledronic acid and secondary prevention of fractures.

  The New England journal of medicine 20071101

• Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.

  European journal of haematology 20071101

• Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20071101

• Zoledronic acid for treatment of Paget's disease of bone.

  Expert opinion on pharmacotherapy 20071101

• Intravenous bisphosphonate-associated osteonecrosis of the jaw.

  Journal of periodontology 20071101

• Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.

  Molecular cancer therapeutics 20071101

• [Advances in the field of osteoporosis].

  La Revue du praticien 20071015

• Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20071001

• Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.

  European urology 20071001

• New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?

  European urology 20071001

• Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20071001

• Re: 'A single zoleledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density' by Saag et al.

  Bone 20071001

• Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20071001

• Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs.

  Journal of veterinary pharmacology and therapeutics 20071001

• Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).

  International journal of laboratory hematology 20071001

• Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.

  Journal of dental research 20071001

• The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

  Cancer research 20071001

• Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zoledronic acid therapy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20071001

• Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.

  Cellular immunology 20071001

• Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070915

• Zoledronic acid-induced IPP/ApppI production in vivo.

  Life sciences 20070908

• Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study.

  Cell biology international 20070901

• Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20070901

• Acute phase response and mineral status following low dose intravenous zoledronic acid in children.

  Bone 20070901

• Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates.

  Chemical research in toxicology 20070901

• Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.

  Japanese journal of clinical oncology 20070901

• Spontaneous bilateral subcapital hip fracture due to multiple myeloma: an 18-month follow-up.

  European journal of cancer care 20070901

• Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.

  Medicina oral, patologia oral y cirugia bucal 20070901

• Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

  The oncologist 20070901

• Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.

  Clinical genitourinary cancer 20070901

• Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.

  Clinical genitourinary cancer 20070901

• The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).

  Journal of experimental & clinical cancer research : CR 20070901

• Yearly zoledronic acid in postmenopausal osteoporosis.

  The New England journal of medicine 20070816

• Yearly zoledronic acid in postmenopausal osteoporosis.

  The New England journal of medicine 20070816

• Yearly zoledronic acid in postmenopausal osteoporosis.

  The New England journal of medicine 20070816

• Yearly zoledronic acid in postmenopausal osteoporosis.

  The New England journal of medicine 20070816

• Yearly zoledronic acid in postmenopausal osteoporosis.

  The New England journal of medicine 20070816

• Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.

  Cancer immunology, immunotherapy : CII 20070801

• Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.

  Blood 20070801

• Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070801

• Bone density in breast cancer: when to intervene?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801

• Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells.

  International journal of oncology 20070801

• Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20070801

• Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801

• Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

  Cancer research 20070801

• Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

  Urology 20070801

• Orofacial pain - a presenting symptom of bisphosphonate associated osteonecrosis of the jaws.

  British dental journal 20070728

• Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer.

  Cancer 20070715

• Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20070701

• A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.

  Leukemia 20070701

• Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

  Bone 20070701

• Bisphosphonates and osteonecrosis of the jaw.

  Rheumatology (Oxford, England) 20070701

• Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20070701

• New and emerging treatments for osteoporosis.

  Current opinion in rheumatology 20070701

• Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.

  BJU international 20070701

• An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.

  Current medical research and opinion 20070701

• Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.

  Journal of immunology (Baltimore, Md. : 1950) 20070701

• Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.

  Urology 20070701

• By the way, doctor. Should I take an intravenous drug for osteoporosis?

  Harvard women's health watch 20070701

• Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.

  Clinical breast cancer 20070701

• [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].

  Nederlands tijdschrift voor geneeskunde 20070630

• Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.

  Cancer letters 20070608

• Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20070601

• Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.

  British journal of haematology 20070601

• Bone turnover 18 months after a single intravenous dose of zoledronic acid.

  International journal of clinical practice 20070601

• Articular damage is associated with intraosseous inflammation in the subchondral bone marrow of joints affected by experimental inflammatory arthritis and is modified by zoledronate treatment.

  The Journal of rheumatology 20070601

• Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• New developments of aminobisphosphonates: the double face of Janus.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070601

• [Mediastinal lymph nodes during the course of a metastatic prostate cancer].

  Actas urologicas espanolas 20070601

• Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.

  British journal of cancer 20070521

• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  The New England journal of medicine 20070503

• Treatments for osteoporosis - looking beyond the HORIZON.

  The New England journal of medicine 20070503

• Alendronate and atrial fibrillation.

  The New England journal of medicine 20070503

• R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.

  Journal of cellular physiology 20070501

• Docetaxel and beyond.

  European urology 20070501

• A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.

  Bone 20070501

• A single infusion of zoledronate prevents bone loss after stroke.

  Stroke 20070501

• Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.

  Calcified tissue international 20070501

• Bisphosphonate treatment as a cause of jaw osteonecrosis.

  Oral diseases 20070501

• The safety of zoledronic acid.

  Expert opinion on drug safety 20070501

• Zoledronic acid prevents bone loss.

  The Lancet. Oncology 20070501

• [Zoledronate-associated end stage renal failure and hypocalcaemia].

  Praxis 20070425

• Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia.

  Leukemia research 20070401

• Effect of zoledronic acid in an L6-L7 rabbit spine fusion model.

  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20070401

• Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.

  The Journal of clinical endocrinology and metabolism 20070401

• Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.

  Bone 20070401

• Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells.

  Leukemia 20070401

• Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978.

  The Journal of urology 20070401

• Male breast cancer with mandibular metastasis. A case report.

  Minerva stomatologica 20070401

• Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.

  International journal of urology : official journal of the Japanese Urological Association 20070401

• Zoledronic acid treatment at home: safety data from an observational prospective trial.

  Journal of palliative medicine 20070401

• Potential effect of zoledronate therapy in heavy proteinuria.

  Clinical nephrology 20070401

• Annual zoledronic acid: is less more?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070320

• Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070320

• The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro.

  Journal of biomedical materials research. Part A 20070315

• The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

  Cancer 20070315

• Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.

  Leukemia research 20070301

• Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070301

• Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070301

• Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070301

• Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20070301

• Use of intravenous bisphosphonates in osteoporosis.

  Current osteoporosis reports 20070301

• Bisphosphonates and jaw osteonecrosis: the UAMS experience.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20070301

• Paraplegia due to extramedullary hematopoiesis in thalassemia treated successfully with radiation therapy.

  Haematologica 20070301

• The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

  Clinical genitourinary cancer 20070301

• Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.

  Clinical lymphoma & myeloma 20070301

• Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.

  Biochemical and biophysical research communications 20070223

• Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

  Journal of the National Cancer Institute 20070221

• Differential effects of bisphosphonates on breast cancer cell lines.

  Cancer letters 20070208

• [Osteonecrosis of the jawbone as a side effect of intravenous treatment with bisphosphonates].

  Nederlands tijdschrift voor geneeskunde 20070203

• Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20070201

• Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events.

  Pharmacotherapy 20070201

• Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer.

  Urology 20070201

• Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.

  British journal of cancer 20070129

• Enhancement of BCG-induced Th1 immune response through Vgamma9Vdelta2 T cell activation with non-peptidic drugs.

  Vaccine 20070122

• Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action.

  Rheumatology international 20070101

• Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.

  Annals of hematology 20070101

• A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20070101

• Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.

  Molecular pharmacology 20070101

• Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways.

  Journal of thrombosis and haemostasis : JTH 20070101

• Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.

  Acta haematologica 20070101

• Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.

  International journal of urology : official journal of the Japanese Urological Association 20070101

• [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].

  Clinical calcium 20070101

• [Molecular mechanism and potential targets for bone metastasis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment.

  Annals of clinical and laboratory science 20070101

• [Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study].

  Recenti progressi in medicina 20070101

• The effect of zoledronate on bone remodeling during the healing process.

  Acta cirurgica brasileira 20070101

• Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.

  Drugs 20070101

• Clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers.

  The International journal of biological markers 20070101

• Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient.

  The International journal of prosthodontics 20070101

• Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20070101

• Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells.

  Endothelium : journal of endothelial cell research 20070101

• Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals.

  American journal of otolaryngology 20070101

• Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.

  Acta oncologica (Stockholm, Sweden) 20070101

• The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.

  Acta oncologica (Stockholm, Sweden) 20070101

• Bisphosphonates and osteonecrosis of the jaw: a retrospective study.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20070101

• Persistent effect of zoledronic acid in Paget's disease.

  Clinical and experimental rheumatology 20070101

• Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats.

  Clinical & experimental metastasis 20070101

• Zoledronic acid - a multiplicity of anti-cancer action.

  Current medicinal chemistry 20070101

• Burden of bone disease.

  European journal of oncology nursing : the official journal of European Oncology Nursing Society 20070101

• Role of the nurse in preserving patients' independence.

  European journal of oncology nursing : the official journal of European Oncology Nursing Society 20070101

• Optimal management of metastatic bone disease.

  European journal of oncology nursing : the official journal of European Oncology Nursing Society 20070101

• The role of nurses in preserving patients' functional independence: Zoledronic acid--evidence and experience in metastatic bone disease.

  European journal of oncology nursing : the official journal of European Oncology Nursing Society 20070101

• Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.

  Medical oncology (Northwood, London, England) 20070101

• Zoledronic acid and clinical fractures and mortality after hip fracture.

  The New England journal of medicine 20070101

• Complications & side effects. Zoledronic acid for thicker bones.

  TreatmentUpdate 20070101

• Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.

  Acta haematologica 20070101

• [Zoledronic acid free adjustment according to renal function: results of pharmacists interventions].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101

• In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells.

  Anticancer research 20070101

• [Use of zoledromic acid on pain control in stages M1b of prostate cancer].

  Actas urologicas espanolas 20070101

• Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.

  British journal of haematology 20061201

• Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.

  Blood 20061201

• The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma.

  Haematologica 20061201

• Jaw osteonecrosis associated with bisphosphonates.

  The New Zealand medical journal 20061201

• Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20061201

• Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061201

• Zoledronic acid in the management of metastatic bone disease.

  Expert opinion on biological therapy 20061201

• Zoledronate: efficacy and safety.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20061201

• CALGB 90202.

  Clinical advances in hematology & oncology : H&O 20061201

• Bisphosphonates.

  Annals of the New York Academy of Sciences 20061201

• [Treatment of hormone-resistant prostate cancer].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20061102

• 'The beneficial effects of zoledronic acid therapy following an acute stroke in rats' by Lee et al.

  Bone 20061101

• Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines.

  The Journal of urology 20061101

• Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.

  The Lancet. Oncology 20061101

• Zoledronic acid palliation in bone-metastatic breast cancer.

  The Lancet. Oncology 20061101

• I'm taking bisphosphonates for my osteoporosis, but I've heard it can cause a serious jaw condition. Is this something I should be concerned about?

  DukeMedicine healthnews 20061101

• [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].

  Medicina clinica 20061028

• [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].

  Medicina clinica 20061021

• Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061020

• A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.

  Bone 20061001

• Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.

  Clinical journal of oncology nursing 20061001

• [Treatment of Paget's disease of bone: importance of the zoledronic acid].

  Arquivos brasileiros de endocrinologia e metabologia 20061001

• Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.

  International journal of cancer 20060901

• Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.

  Annals of hematology 20060901

• Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

  The Journal of urology 20060901

• Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation.

  Internal medicine journal 20060901

• Zoledronic acid modulates function and differentiation of myeloid cells.

  Haematologica 20060901

• Zoledronic acid for the treatment of thalassemia-induced osteonecrosis.

  Haematologica 20060901

• The effect of zoledronic acid on the function and differentiation of myeloid cells.

  Haematologica 20060901

• Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.

  Haematologica 20060901

• A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.

  Calcified tissue international 20060901

• Serious ocular complications of zoledronate.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20060901

• Scleritis complicating zoledronic acid infusion.

  Clinical lymphoma & myeloma 20060901

• [Osteonecrosis associated with the use of biphosphonates: Case report].

  Revista medica de Chile 20060901

• The beneficial effect of intravenous zoledronic acid therapy following an acute stroke in rats.

  Bone 20060801

• Quantitative and reliable in vitro method combining scanning electron microscopy and image analysis for the screening of osteotropic modulators.

  Microscopy research and technique 20060801

• Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.

  Cancer 20060801

• Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.

  Cancer 20060801

• Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20060801

• Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.

  Mayo Clinic proceedings 20060801

• Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.

  Mayo Clinic proceedings 20060801

• Efficacy of zoledronate against neuroblastoma.

  Surgery 20060801

• Bisphosphonates: case report of nonsurgical periodontal therapy and osteochemonecrosis.

  The International journal of periodontics & restorative dentistry 20060801

• Nursing implications of androgen deprivation therapy-associated bone loss.

  Urologic nursing 20060801

• Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.

  Wiener klinische Wochenschrift 20060801

• Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.

  Acta bio-medica : Atenei Parmensis 20060801

• Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.

  Bone 20060701

• Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.

  International journal of oral and maxillofacial surgery 20060701

• Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

  Haematologica 20060701

• Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.

  Dento maxillo facial radiology 20060701

• In vitro inhibition of matrix metalloproteinase activity in tracheal epithelial lining fluid from horses with recurrent airway obstruction.

  American journal of veterinary research 20060701

• Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20060701

• Synergistic antimyeloma effects of zoledronate and simvastatin.

  Anti-cancer drugs 20060701

• [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].

  MMW Fortschritte der Medizin 20060622

• Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Management of the adverse effects associated with intravenous bisphosphonates.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060601

• Anticancer effects of zoledronic acid against human osteosarcoma cells.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20060601

• Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.

  BJU international 20060601

• Acute retinal pigment epitheliitis associated with intravenous bisphosphonate.

  The British journal of ophthalmology 20060601

• Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.

  The Lancet. Oncology 20060601

• Bisphosphonate-associated arthritis.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20060601

• Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.

  Nature clinical practice. Oncology 20060601

• [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].

  Hinyokika kiyo. Acta urologica Japonica 20060601

• [Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].

  Ugeskrift for laeger 20060522

• The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.

  Proceedings of the National Academy of Sciences of the United States of America 20060516

• First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.

  European journal of haematology 20060501

• Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.

  Oncology reports 20060501

• The role of bisphosphonates in the management of prostate cancer.

  Current oncology reports 20060501

• Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis.

  Arthritis and rheumatism 20060501

• Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060501

• [Therapeutic options for hormone-refractory prostate cancer].

  Der Urologe. Ausg. A 20060501

• [Diphosphonates can cause necrosis of the jaw. Patients with malignant skeletal diseases are at risk].

  Lakartidningen 20060501

• [Bisphosphonates for bone metastasis of malignant tumor].

  Clinical calcium 20060401

• Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy.

  Journal of periodontology 20060401

• Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.

  Seminars in oncology 20060401

• Home infusions of biphosphonate in cancer patients: a prospective study.

  Journal of chemotherapy (Florence, Italy) 20060401

• Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?

  Nature clinical practice. Rheumatology 20060401

• Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060320

• Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb.

  Bone 20060301

• Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.

  Oral oncology 20060301

• Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute.

  Bone 20060301

• [Bisphosphonate-associated osteonecrosis of the jaw].

  Mund-, Kiefer- und Gesichtschirurgie : MKG 20060301

• Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study.

  Cell biology international 20060301

• Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.

  Oncology reports 20060301

• Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.

  BJU international 20060301

• The use of zoledronic acid for Paget's disease of bone.

  Current osteoporosis reports 20060301

• Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.

  The New Zealand dental journal 20060301

• The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.

  Clinical genitourinary cancer 20060301

• Summaries for patients. Zolendronic acid prevents bone loss after liver transplantation.

  Annals of internal medicine 20060221

• Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.

  Annals of internal medicine 20060221

• Pharmacological therapy of Paget's and other metabolic bone diseases.

  Bone 20060201

• [Two cases of stage IV breast cancer with severe hypercalcemia].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.

  Breast (Edinburgh, Scotland) 20060201

• Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling.

  Acta orthopaedica 20060201

• Relationship between periodontal disease and systemic diseases.

  Texas dental journal 20060201

• Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.

  Cancer chemotherapy and pharmacology 20060101

• Two cases of endometrial cancer diagnosis associated with bone metastasis.

  Gynecologic and obstetric investigation 20060101

• Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats.

  Journal of biomedical materials research. Part A 20060101

• Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication.

  International immunology 20060101

• Osteonecrosis of the jaws and bisphosphonates. Report of three cases.

  Medicina oral, patologia oral y cirugia bucal 20060101

• Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.

  Urologic oncology 20060101

• Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.

  BMC cancer 20060101

• A prospective randomized controlled clinical trial of zoledronic acid for bone metastases.

  The American journal of hospice & palliative care 20060101

• Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.

  Anticancer research 20060101

• Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells.

  Anticancer research 20060101

• Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.

  BMC cancer 20060101

• Jaw complications in breast and prostate cancer patients treated with zoledronic acid.

  Acta oncologica (Stockholm, Sweden) 20060101

• Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.

  Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20060101

• Hypercalcemia of malignancy remains a clinically relevant problem.

  Cancer journal (Sudbury, Mass.) 20060101

• Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.

  Medical oncology (Northwood, London, England) 20060101

• Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.

  Oncology 20060101

• Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.

  Cytotherapy 20060101

• The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.

  Clinical & experimental metastasis 20060101

• Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?

  Acta oncologica (Stockholm, Sweden) 20060101

• Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model.

  Journal of computer assisted tomography 20060101

• Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.

  The oncologist 20060101

• Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats.

  BMC musculoskeletal disorders 20060101

• Drug induced osteonecrosis of the jaws.

  The Journal of the Tennessee Dental Association 20060101

• Case studies in metastatic bone disease: understanding the unique nature of bone loss due to malignancy.

  ONS news 20060101

• In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells.

  Breast cancer research : BCR 20060101

• Fever with rash following zolendronic acid administration.

  Clinical and experimental rheumatology 20060101

• [Zoledronate-related maxillary osteonecrosis].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Sore mandible. Bisphosphonate-associated osteonecrosis.

  General dentistry 20060101

• [Acute kidney failure caused by zoledronic acid (Zometa)].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20060101

• Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.

  Anticancer research 20060101

• [Avascular osteonecrosis of the jaws induced by diphosphonates].

  Therapie 20060101

• Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.

  The journal of supportive oncology 20060101

• Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

  Drug safety 20060101

• The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.

  Acta poloniae pharmaceutica 20060101

• A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer.

  Oncology 20060101

• Consumer groups look to improve adverse event reporting systems.

  Journal of the National Cancer Institute 20051221

• Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.

  Biochemical and biophysical research communications 20051216

• Paget's disease and bisphosphonates.

  The New England journal of medicine 20051215

• Paget's disease and bisphosphonates.

  The New England journal of medicine 20051215

• [Optimizing therapy in Paget disease].

  MMW Fortschritte der Medizin 20051215

• Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20051201

• [Zoledronic acid in the treatment of prostate cancer].

  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20051201

• Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?

  Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20051201

• Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.

  Cancer 20051201

• Newer drug treatments: their effects on fracture prevention.

  Best practice & research. Clinical rheumatology 20051201

• Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.

  Internal medicine journal 20051201

• Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051201

• Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

  Endocrine-related cancer 20051201

• The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution.

  Clinical orthopaedics and related research 20051201

• [Phase II randomized clinical trail of zoledronic acid in treating metastatic bone pain of malignancy].

  Ai zheng = Aizheng = Chinese journal of cancer 20051201

• Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog.

  Calcified tissue international 20051201

• Acute renal effects of intravenous bisphosphonates in the rat.

  Basic & clinical pharmacology & toxicology 20051201

• Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge.

  Journal of the American Dental Association (1939) 20051201

• By the way, doctor. I've heard that taking Fosamax for a long time causes the jawbone to deteriorate. Do you know anything about this?

  Harvard women's health watch 20051201

• Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention.

  The Medical journal of Australia 20051121

• RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro.

  Blood 20051101

• Radiosensitizing effect of zoledronic acid in small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20051101

• Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.

  Leukemia 20051101

• Zoledronic acid sensitizes tumor cells to radiation: in response to Algur et al. (Int J Radiat Oncol Biol Phys 2005;61:535-542).

  International journal of radiation oncology, biology, physics 20051101

• Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20051101

• Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.

  BJU international 20051101

• Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051101

• Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20051101

• Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.

  Urology 20051101

• [Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20051101

• S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.

  Clinical advances in hematology & oncology : H&O 20051101

• Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.

  Cancer 20051015

• [Osteoporosis and anti-androgenic therapy in case of prostate cancer].

  Revue medicale suisse 20051005

• Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051001

• Alleviation of polyarticular syndrome in multicentric reticulohistiocytosis with intravenous zoledronate.

  Annals of the rheumatic diseases 20051001

• Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.

  Anti-cancer drugs 20051001

• Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.

  Journal of endodontics 20051001

• Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20051001

• The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.

  Journal of chemotherapy (Florence, Italy) 20051001

• [Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20051001

• A validated stability indicating ion-pair RP-LC method for zoledronic acid.

  Journal of pharmaceutical and biomedical analysis 20050915

• [Bisphosphonates-related jaw osteonecrosis].

  Presse medicale (Paris, France : 1983) 20050910

• Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC).

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20050901

• Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.

  Anti-cancer drugs 20050901

• Pagetic hydrocephalus treated with zoledronate.

  Annals of the rheumatic diseases 20050901

• Gorham's disease of the mandible mimicking periodontal disease on radiograph.

  Journal of clinical periodontology 20050901

• Treatment of Paget's disease--taming the wild osteoclast.

  The New England journal of medicine 20050901

• Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

  The New England journal of medicine 20050901

• Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.

  Urology 20050901

• Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis.

  American journal of veterinary research 20050901

• Important drug precaution for dental health professionals with patients being treated for cancer.

  Texas dental journal 20050901

• Studies in osteonecrosis.

  British dental journal 20050827

• Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.

  International journal of cancer 20050810

• Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050801

• Treatment of Gorham's disease with zoledronic acid.

  Oral oncology 20050801

• Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801

• The effect of bisphosphonates and titanium particles on osteoblasts: an in vitro study.

  The Journal of bone and joint surgery. British volume 20050801

• Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.

  British journal of haematology 20050801

• Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.

  Clinical therapeutics 20050801

• Evolving therapeutic role of bisphosphonates in multiple myeloma.

  British journal of cancer 20050725

• Osteonecrosis of the jaw and bisphosphonates.

  The New England journal of medicine 20050707

• Osteonecrosis of the jaw and bisphosphonates.

  The New England journal of medicine 20050707

• Osteonecrosis of the jaw and bisphosphonates.

  The New England journal of medicine 20050707

• Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.

  Bone 20050701

• Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.

  Cancer 20050701

• Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.

  Medicina oral, patologia oral y cirugia bucal 20050701

• Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20050701

• [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].

  Mund-, Kiefer- und Gesichtschirurgie : MKG 20050701

• Stimulation of bone formation by zoledronic acid in particle-induced osteolysis.

  Biomaterials 20050601

• The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.

  European journal of haematology 20050601

• New therapeutic agents for the treatment of bone diseases.

  Expert opinion on biological therapy 20050601

• Ask us: Some drugs affect tooth movement.

  American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 20050601

• Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.

  Clinical prostate cancer 20050601

• Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.

  Clinical breast cancer 20050601

• [A comparison of the antiresorptive effects of bisphosphonates and statins on polyethylene particle-induced osteolysis].

  Biomedizinische Technik. Biomedical engineering 20050601

• Current status of treatment for patients with metastatic prostate cancer.

  The Canadian journal of urology 20050601

• Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.

  Hematology (Amsterdam, Netherlands) 20050601

• Special precautions.

  British dental journal 20050528

• Longer-lasting osteoporosis drugs sought.

  JAMA 20050525

• Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.

  British journal of cancer 20050523

• Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• Profound hypocalcaemia after zoledronic acid treatment.

  The Medical journal of Australia 20050502

• The decrease of particle-induced osteolysis after a single dose of bisphosphonate.

  Biomaterials 20050501

• Novel biomaterials for bisphosphonate delivery.

  Biomaterials 20050501

• Bisphosphonates in breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050501

• The role of bisphosphonates in the treatment of prostate cancer.

  BJU international 20050501

• Regarding 'recommendations for zoledronic acid treatment of patients with bone metastases'.

  The oncologist 20050501

• The issue of renal safety of zoledronic acid from a nephrologist's point of view.

  The oncologist 20050501

• 'Safety and convenience of a 15-minute infusion of zoledronic acid': not so safe.

  The oncologist 20050501

• Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050501

• Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.

  Cancer research 20050501

• Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations.

  Biological trace element research 20050501

• Bisphosphonates, cancer, and osteonecrosis--a single practice experience.

  Delaware medical journal 20050501

• Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.

  Current medical research and opinion 20050501

• Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors.

  Cancer 20050415

• Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.

  Leukemia 20050401

• [Rapid drug information].

  Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 20050401

• Zoledronic acid: past, present and future roles in cancer treatment.

  Future oncology (London, England) 20050401

• Management of bone metastases in breast cancer.

  Current treatment options in oncology 20050301

• Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

  British journal of haematology 20050301

• Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20050301

• Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA.

  IDrugs : the investigational drugs journal 20050301

• Zoledronic acid causes enhancement of bone growth into porous implants.

  The Journal of bone and joint surgery. British volume 20050301

• Rapid prevention of vertebral fractures associated with osteoporosis.

  Orthopedics 20050301

• [Multiple myeloma--recent advances in diagnosis and treatment].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• Zoledronic acid prevents cancer treatment-induced bone loss.

  Oncology (Williston Park, N.Y.) 20050301

• Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.

  Clinical lung cancer 20050301

• Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  Journal of the National Cancer Institute 20050202

• Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy.

  Eye (London, England) 20050201

• Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation.

  The Journal of clinical endocrinology and metabolism 20050201

• The role of bisphosphonates in hormone-refractory prostate cancer.

  World journal of urology 20050201

• Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines.

  International journal of radiation oncology, biology, physics 20050201

• Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.

  American journal of clinical oncology 20050201

• Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy.

  Journal (Canadian Dental Association) 20050201

• Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.

  Tennessee medicine : journal of the Tennessee Medical Association 20050201

• [Use of zoledronic acid for high risk prostate cancer patients].

  Der Urologe. Ausg. A 20050201

• Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.

  Clinical breast cancer 20050201

• Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman.

  Aging clinical and experimental research 20050201

• CALGB 78909: Phase III trial of intravenous zoledronic acid in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.

  Clinical advances in hematology & oncology : H&O 20050201

• Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.

  International journal of cancer 20050120

• Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

  Journal of the National Cancer Institute 20050105

• Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  Journal of the National Cancer Institute 20050105

• Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.

  Lung cancer (Amsterdam, Netherlands) 20050101

• In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.

  Anti-cancer drugs 20050101

• Recommendations for zoledronic acid treatment of patients with bone metastases.

  The oncologist 20050101

• Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid.

  The oncologist 20050101

• Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration.

  Bone 20050101

• Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.

  Urology 20050101

• Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.

  Urology 20050101

• A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.

  Japanese journal of clinical oncology 20050101

• The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.

  Oncology 20050101

• The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.

  Oncology 20050101

• Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.

  Treatments in endocrinology 20050101

• Nonhealing extraction site.

  General dentistry 20050101

• Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells.

  Oncology research 20050101

• Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.

  Anticancer research 20050101

• Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.

  The Annals of pharmacotherapy 20050101

• Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline.

  Medical oncology (Northwood, London, England) 20050101

• Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma.

  Medical oncology (Northwood, London, England) 20050101

• Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.

  Prostate cancer and prostatic diseases 20050101

• Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.

  BMC cancer 20050101

• Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.

  Acta oncologica (Stockholm, Sweden) 20050101

• Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.

  Oncology 20050101

• Reversible metastatic visceral calcification detected by 99mTc-methylene diphosphonate bone scanning in breast cancer.

  Journal of bone and mineral metabolism 20050101

• Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.

  Acta oncologica (Stockholm, Sweden) 20050101

• Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.

  Journal of pain & palliative care pharmacotherapy 20050101

• Drug-induced osteonecrosis of the jaws: a new clinical entity.

  CDS review 20050101

• Anti-tumour activity of zoledronic acid.

  Cancer treatment reviews 20050101

• Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.

  Cancer treatment reviews 20050101

• Hypercalcemia and local production of parathyroid hormone-related protein by a perisellar rhabdomyosarcoma after remote pituitary irradiation.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20050101

• Moving into the future: treatment of bone metastases and beyond.

  Cancer treatment reviews 20050101

• Zoledronic acid(ZOMETA): a significant improvement in the bone metastases.

  Pathology oncology research : POR 20050101

• Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer.

  BMC cancer 20050101

• Bone metabolic effects of single-dose zoledronate in healthy dogs.

  Journal of veterinary internal medicine 20050101

• [Treatment of Paget's disease of bone with zoledronic acid].

  Revue medicale de Bruxelles 20050101

• [Zoledronic acid and osseous pathologies in the course of neoplasia. Part II].

  Tumori 20050101

• [Zoledronic acid and bone pathology in the course of neoplasia. Part I].

  Tumori 20050101

• Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws.

  LDA journal 20050101

• The buzz about bisphosphonates.

  LDA journal 20050101

• Zometa in the treatment of diseminated prostate cancer.

  Acta chirurgica Iugoslavica 20050101

• Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition.

  The Biochemical journal 20041215

• Zoledronic acid-associated thrombotic thrombocytopenic purpura.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041201

• Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041201

• Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.

  Seminars in oncology 20041201

• Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.

  Oncology reports 20041101

• Short-term safety assessment in the use of intravenous zoledronic acid in children.

  The Journal of pediatrics 20041101

• Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.

  The Journal of urology 20041101

• Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.

  Clinical lung cancer 20041101

• Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041015

• Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  Journal of the National Cancer Institute 20041006

• Osteoclast-targeted therapy for prostate cancer.

  Current treatment options in oncology 20041001

• Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20041001

• Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer.

  Gynecologic oncology 20041001

• Bisphosphonates in the treatment of skeletal metastases.

  Seminars in oncology 20041001

• The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus.

  Revista do Hospital das Clinicas 20041001

• Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040915

• The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.

  Oncogene 20040909

• Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20040901

• Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20040901

• Zoledronate-induced remission of acute panmyelosis with myelofibrosis.

  European journal of haematology 20040901

• Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.

  European urology 20040901

• Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.

  BJU international 20040901

• High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.

  Cancer 20040901

• An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

  The Journal of clinical investigation 20040901

• Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.

  Clinical orthopaedics and related research 20040901

• Intravenous bisphosphonates and osteonecrosis.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20040901

• Successful treatment of SAPHO syndrome with zoledronic acid.

  Arthritis and rheumatism 20040901

• Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.

  Clinical prostate cancer 20040901

• In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.

  Anti-cancer drugs 20040901

• Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.

  British journal of cancer 20040816

• Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  Journal of the National Cancer Institute 20040804

• Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.

  British journal of haematology 20040801

• Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.

  Calcified tissue international 20040701

• Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.

  Current oncology reports 20040701

• Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation.

  BJU international 20040701

• Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040701

• Bisphosphonates: environmental protection for the joint?

  Arthritis and rheumatism 20040701

• Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.

  Arthritis and rheumatism 20040701

• Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.

  Arthritis and rheumatism 20040701

• [Separation of zoledronic acid and its related substances by ion-pair reversed-phase high performance liquid chromatography].

  Se pu = Chinese journal of chromatography 20040701

• Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

  Cancer 20040615

• Hypocalcaemia after intravenous bisphosphonate: read the product information first.

  BMJ (Clinical research ed.) 20040612

• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  Journal of the National Cancer Institute 20040602

• Bisphosphonate infusions: patient preference, safety and clinic use.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20040601

• Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040601

• The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair.

  Current medical research and opinion 20040601

• Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells.

  The Prostate 20040501

• High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.

  Cancer 20040501

• Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

  Cancer 20040501

• Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.

  Urology 20040501

• From labdanes to drimanes. Degradation of the side chain of dihydrozamoranic acid.

  Molecules (Basel, Switzerland) 20040430

• Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid.

  British journal of haematology 20040401

• Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer.

  The Journal of urology 20040401

• Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa.

  The Annals of pharmacotherapy 20040301

• Nephrotoxicity of third-generation, intravenous bisphosphonates.

  Toxicology 20040301

• Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases.

  Clinical lung cancer 20040301

• Severe hypocalcaemia after being given intravenous bisphosphonate.

  BMJ (Clinical research ed.) 20040207

• Heteromeric geranyl diphosphate synthase from mint: construction of a functional fusion protein and inhibition by bisphosphonate substrate analogs.

  Archives of biochemistry and biophysics 20040201

• Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.

  Medical care 20040201

• Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.

  Acta radiologica (Stockholm, Sweden : 1987) 20040201

• Role of bisphosphonates in prostate cancer.

  European urology 20040101

• Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation.

  Kidney international 20040101

• Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.

  Cancer 20040101

• Hypercalcemia of malignancy.

  Seminars in nephrology 20040101

• The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro.

  Bone 20040101

• The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040101

• Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.

  International journal of hematology 20040101

• Advances in the use of bisphosphonates in the prostate cancer setting.

  Prostate cancer and prostatic diseases 20040101

• Hypocalcemic effect of zoledronic acid or other bisphosphonates may contribute to their antiangiogenic properties.

  Medical hypotheses 20040101

• Zoledronic acid: a review of its use in patients with advanced cancer.

  Drugs 20040101

• Safety and convenience of a 15-minute infusion of zoledronic acid.

  The oncologist 20040101

• [Ibandronate: keep life in motion].

  Tumori 20040101

• Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?

  Medical hypotheses 20040101

• Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.

  The oncologist 20040101

• Management of androgen-independent prostate cancer.

  Cancer control : journal of the Moffitt Cancer Center 20040101

• Hypercalcemia and gallium nitrate.

  The journal of supportive oncology 20040101

• Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.

  The Journal of urology 20031201

• Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

  The Journal of urology 20031201

• The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.

  International journal of hematology 20031201

• [Prostatic carcinoma. Zoledronic acid raises bone density].

  Aktuelle Urologie 20031201

• Treatment strategies for myeloma bone disease.

  Oncology (Williston Park, N.Y.) 20031201

• Bisphosphonates and avascular necrosis of the jaws.

  Australian dental journal 20031201

• Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.

  Journal of experimental & clinical cancer research : CR 20031201

• 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.

  Journal of medicinal chemistry 20031120

• Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20031101

• Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20031101

• Bisphosphonate therapy in the oncology setting.

  Expert opinion on emerging drugs 20031101

• Zoledronic acid: a new parenteral bisphosphonate.

  Clinical therapeutics 20031101

• Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.

  The Journal of biological chemistry 20031031

• Renal failure with the use of zoledronic acid.

  The New England journal of medicine 20031023

• Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.

  Cancer 20031015

• Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.

  International journal of cancer 20031010

• Avascular necrosis of the jaws: risk factors in metastatic cancer patients.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20031001

• Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.

  Seminars in oncology 20031001

• Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.

  Seminars in hematology 20031001

• The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.

  Toxicology 20030930

• The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.

  Blood 20030915

• Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

  Blood 20030915

• Bisphosphonates in prostate cancer: where are we and where should we go?

  Journal of the National Cancer Institute 20030903

• Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.

  Journal of the National Cancer Institute 20030903

• A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

  Journal of the National Cancer Institute 20030903

• Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

  Cancer 20030901

• Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20030901

• The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia.

  Palliative medicine 20030901

• Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis.

  The Annals of otology, rhinology, and laryngology 20030901

• Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030815

• Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  Journal of the National Cancer Institute 20030806

• Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.

  American journal of clinical oncology 20030801

• Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Cancer patients with bone complications prefer infusion of zoledronic acid.

  Oncology (Williston Park, N.Y.) 20030801

• Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.

  Bone 20030801

• Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.

  Breast (Edinburgh, Scotland) 20030801

• The anti-tumor potential of zoledronic acid.

  Breast (Edinburgh, Scotland) 20030801

• Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.

  Breast (Edinburgh, Scotland) 20030801

• Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.

  Aging clinical and experimental research 20030801

• Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

  Kidney international 20030701

• Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.

  The Journal of urology 20030701

• Bisphosphonates: new indications and methods of administration.

  Current opinion in rheumatology 20030701

• The use of bisphosphonates in prostate cancer.

  BJU international 20030701

• How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics.

  British journal of haematology 20030701

• Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20030701

• Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

  British journal of cancer 20030616

• Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

  The Journal of urology 20030601

• Highlights from the 98th annual meeting of the American Urological Association Chicago, IL.

  Clinical prostate cancer 20030601

• New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.

  British journal of cancer 20030519

• Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.

  The Lancet. Oncology 20030501

• Selected therapy-related clinical research topics in osteoporosis.

  Journal of pediatric endocrinology & metabolism : JPEM 20030501

• In focus: prostate cancer.

  Clinical advances in hematology & oncology : H&O 20030501

• Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.

  Calcified tissue international 20030401

• Zoledronic acid: a new advance in managing skeletal events in prostate cancer.

  BJU international 20030401

• Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.

  Expert opinion on pharmacotherapy 20030401

• Zoledronic acid (Zometa) use in bone disease.

  Expert review of anticancer therapy 20030401

• [The role of bisphosphonates in the treatment of bone metastases from urogenital cancer ].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20030401

• The role of intravenous zoledronic acid in the management of high-risk prostate cancer.

  Current opinion in urology 20030301

• Zoledronate treatment in active Paget's disease.

  Annals of the rheumatic diseases 20030301

• Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20030301

• Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.

  Kidney international 20030301

• Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  Journal of the National Cancer Institute 20030219

• Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  Journal of the National Cancer Institute 20030219

• Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  Journal of the National Cancer Institute 20030219

• Bisphosphonates and metastatic breast carcinoma.

  Cancer 20030201

• The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function.

  Journal of clinical pharmacology 20030201

• Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.

  Drugs 20030101

• Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.

  Clinical journal of oncology nursing 20030101

• Bisphosphonates in the management of metastatic prostate cancer.

  Oncology 20030101

• Bone loss and the evolving role of bisphosphonate therapy in prostate cancer.

  Urologic oncology 20030101

• Pharmacological treatments for prostate cancer.

  Expert opinion on investigational drugs 20021201

• Monosodium [1-hydroxy-2-(1H-imidazol-3-ium-4-yl)ethane-1,1-diyl]bis(phosphonate) tetrahydrate (monosodium isozoledronate).

  Acta crystallographica. Section C, Crystal structure communications 20021201

• Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.

  Pain 20021201

• Advances in the biology and treatment of myeloma bone disease.

  Seminars in oncology 20021201

• Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.

  American journal of clinical oncology 20021201

• Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.

  American journal of clinical oncology 20021201

• Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.

  American journal of clinical oncology 20021201

• Preclinical pharmacology of zoledronic acid.

  Seminars in oncology 20021201

• Treatment of hypercalcemia of malignancy with bisphosphonates.

  Seminars in oncology 20021201

• Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.

  Seminars in oncology 20021201

• Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.

  Seminars in oncology 20021201

• Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.

  Urologic nursing 20021201

• Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone.

  Clinical prostate cancer 20021201

• Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

  Cancer research 20021115

• Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine.

  Journal of pharmaceutical and biomedical analysis 20021107

• Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.

  British journal of haematology 20021101

• Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.

  British journal of haematology 20021101

• Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.

  Journal of clinical pharmacology 20021101

• A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  Journal of the National Cancer Institute 20021002

• The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.

  International journal of oncology 20021001

• Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.

  Cancer research 20021001

• [Bisphosphonates in bone metastases. Fewer fractures, less pain].

  MMW Fortschritte der Medizin 20020926

• Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

  The Journal of pharmacology and experimental therapeutics 20020901

• American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020901

• Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).

  Journal of medicinal chemistry 20020815

• Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.

  Statistics in medicine 20020715

• Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.

  Expert opinion on pharmacotherapy 20020701

• Novel therapeutic options for osteoporosis.

  Current opinion in rheumatology 20020701

• Osteoporosis: challenges and new opportunities for therapy.

  Current opinion in drug discovery & development 20020701

• New drugs 2002, part III.

  Nursing 20020701

• Bisphosphonates and osteoporosis.

  The New England journal of medicine 20020627

• Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.

  Journal of endocrinological investigation 20020601

• Novel approaches to the management of bone metastases in patients with breast cancer.

  Seminars in oncology 20020601

• Zoledronic acid is effective in the treatment of prostate cancer patients with bone metastases.

  Clinical prostate cancer 20020601

• The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.

  British journal of cancer 20020506

• FDA approves ZOMETA for treatment of cancer-related bone complications.

  Expert review of anticancer therapy 20020401

• Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

  Biochemical and biophysical research communications 20020301

• The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage.

  Osteoarthritis and cartilage 20020301

• Bisphosphonates and osteoporosis.

  The New England journal of medicine 20020227

• Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

  The New England journal of medicine 20020227

• Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

  British journal of haematology 20020201

• Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.

  Breast cancer research and treatment 20020201

• Multiple myeloma: present and future.

  Current opinion in oncology 20020101

• Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.

  Cancer practice 20020101

• Electrolyte abnormalities with zoledronic acid therapy.

  Cancer journal (Sudbury, Mass.) 20020101

• U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.

  The oncologist 20020101

• Zoledronic acid.

  Clinical journal of oncology nursing 20020101

• The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

  Cancer investigation 20020101

• Zoledronic acid improves the mechanical properties of normal and healing bone.

  Clinical biomechanics (Bristol, Avon) 20020101

• Bisphosphonate therapy in multiple myeloma: past, present, future.

  European journal of haematology 20020101

• The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.

  The oncologist 20020101

• The use of bisphosphonates in patients with breast cancer.

  Cancer control : journal of the Moffitt Cancer Center 20020101

• Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).

  Acta poloniae pharmaceutica 20020101

• Zolendronate (zometa).

  The Medical letter on drugs and therapeutics 20011210

• Advances in the biology and treatment of myeloma bone disease.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20011115

• Conventional treatment of hypercalcemia of malignancy.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20011115

• Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20011101

• From the Food and Drug Administration.

  JAMA 20011003

• New bisphosphonic acid approved by FDA.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20011001

• A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20011001

• FDA grants priority review for ZOMETA.

  Expert review of anticancer therapy 20011001

• Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison.

  Pharmacology & toxicology 20010901

• [Bisphosphonates in the treatment of breast carcinoma].

  Polskie Archiwum Medycyny Wewnetrznej 20010801

• Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010715

• [Tumor-induced hypercalcemia. Review of bisphosphonate treatment].

  La Revue de medecine interne 20010701

• The effects of MMP inhibitors on human salivary MMP activity and caries progression in rats.

  Journal of dental research 20010601

• Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates.

  International journal of palliative nursing 20010601

• The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.

  Bone 20010501

• Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.

  Cancer 20010401

• The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

  British journal of cancer 20010401

• Unmet needs in metastatic bone disease and its complications: is progress possible?

  Seminars in oncology 20010401

• Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies.

  Seminars in oncology 20010401

• The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.

  Seminars in oncology 20010401

• Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.

  Seminars in oncology 20010401

• Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.

  Seminars in oncology 20010401

• Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.

  Seminars in oncology 20010401

• Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease.

  Seminars in oncology 20010401

• Bisphosphonate treatment inhibits the growth of prostate cancer cells.

  Cancer research 20010315

• [Bone metastasis. Can a new bisphosphonate offer control?].

  MMW Fortschritte der Medizin 20010301

• A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010301

• Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010115

• A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.

  Cancer 20010101

• Zoledronic acid.

  Drugs 20010101

• Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

  Cancer journal (Sudbury, Mass.) 20010101

• Bisphosphonates induce breast cancer cell death in vitro.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20001101

• Bisphosphonates induce apoptosis in human breast cancer cell lines.

  British journal of cancer 20000401

• An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.

  Calcified tissue international 19971101

• Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 19940501